Frameworks for Progress

The Michael J. Fox Foundation for Parkinson’s Research
2016 Annual Report
The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today.
The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today.
Dear Friend,

Each year, we are honored to share how your unflagging determination and sheer generosity have fortified our mission to do whatever it takes to drive research. As a year full of new endeavors and tremendous growth, 2016 was no exception.

We still have much to do, but your dedication is building a better future for the millions living with Parkinson's.

I'm so grateful for your friendship. Together, I have no doubt that we will cure Parkinson's.

The question most frequently asked of The Michael J. Fox Foundation (MJFF) is: “How close are we to a cure for Parkinson’s disease?” With nearly $750 million in Parkinson’s disease (PD) research funded to date, the simplest answer is: closer than ever.

Today’s PD drug development pipeline demonstrates a richness and vibrancy we could only dream of a few short years ago.

But nothing is simple, least of all brain research, and every promising step forward reveals complex new challenges for our problem-solving. As you’ll read in this report, our community increasingly is called on not just to provide funding for the most important research projects in the Parkinson's space, but also to engage with MJFF as we lead and coordinate wide-ranging initiatives that help advance the entire field — frameworks, as it were, for progress.

In the Foundation’s short history, Parkinson’s drug development has experienced a metamorphosis, and it is fair to say that the state of Parkinson’s science as a whole has meaningfully advanced. Multiple scientific breakthroughs, promising new leads and powerful information technology have combined to set the stage for better disease understanding from the patients themselves.

Our on-staff PhD-trained neuroscientists paired with business-trained project managers are identifying, vetting and advancing the most promising ideas in Parkinson’s research, building a portfolio that includes investigations of over 1,000 drug targets to date.
A Note from Michael

Dear Friend,

Each year, we are honored to share how your unflagging determination and sheer generosity have fortified our mission to do whatever it takes to drive research. As a year full of new endeavors and tremendous growth, 2016 was no exception.

We still have much to do, but your dedication is building a better future for the millions living with Parkinson’s.

I’m so grateful for your friendship. Together, I have no doubt that we will cure Parkinson’s.

An Update from the CEO and the Co-Founder

The question most frequently asked of The Michael J. Fox Foundation (MJFF) is: “How close are we to a cure for Parkinson’s disease?” With nearly $750 million in Parkinson’s disease (PD) research funded to date, the simplest answer is: closer than ever.

Today’s PD drug development pipeline demonstrates a richness and vibrancy we could only dream of a few short years ago.

But nothing is simple, least of all brain research, and every promising step forward reveals complex new challenges for our problem-solving. As you’ll read in this report, our community increasingly is called on not just to provide funding for the most important research projects in the Parkinson’s space, but also to engage with MJFF as we lead and coordinate wide-ranging initiatives that help advance the entire field — frameworks, as it were, for progress.

In the Foundation’s short history, Parkinson’s drug development has experienced a metamorphosis, and it is fair to say that the state of Parkinson’s science as a whole has meaningfully advanced. Multiple scientific breakthroughs, promising new leads and powerful information technology have combined to set the stage for better disease understanding from the patients themselves.

Our on-staff PhD-trained neuroscientists paired with business-trained project managers are identifying, vetting and advancing the most promising ideas in Parkinson’s research, building a portfolio that includes investigations of over 1,000 drug targets to date.
When a promising target demonstrates sustained potential to benefit people with Parkinson’s, we move quickly to coordinate an entire field of activity in support of its continued forward movement. We tackle roadblocks head-on, providing researchers with resources to generate data and build the case for high-impact ideas, and sophisticated tools that can help science move through testing and toward regulatory approval faster. This includes characterizing molecular biology, developing strategies to objectively measure pathology and treatment effects, assembling patient cohorts, and creating technology infrastructure to gather and analyze “big data” for use by researchers in MJFF-led and independent studies.

And, it’s clear that our Foundation’s “de-risking” method — a critical framework for progress — is working. Today, several symptomatic therapies for motor and non-motor symptoms are in Phase III clinical testing, with one or more expected to file for FDA approval within the calendar year; compare that to the PD landscape as recently as 2011, when not a single Parkinson’s therapy was being tested in late-stage clinical trials. And there are no fewer than nine disease-modifying therapies advancing through clinical testing that could slow, stop or even reverse progression of PD — something no current treatment is proven to do.

This progress is set against the backdrop of a new era of patient power, with a seismic opportunity for patients to partner with scientists to influence research design and outcomes. Whether volunteering for traditional or virtual clinical trials, advocating for public policy or — like those honored in this report — providing significant financial support for our work, the Parkinson’s community is more committed than ever before to getting involved. That’s why we’ve restructured our staff to add a Community Engagement team, our newest framework dedicated to helping patients and their loved ones navigate the broad range of multi-faceted opportunities to play a personal role in our mission.

Any truly patient-centric program starts from the proposition that patients are the true experts on living with disease. Today, thousands of patients and their loved ones have enrolled in Fox Insight (foxinsight.org), our online clinical study, helping researchers gain a holistic understanding of PD and revolutionizing Parkinson’s research by contributing PROs (patient-reported outcomes) on disease course, symptom progression and treatment outcomes, among other vital data. These participants are part of a growing community of citizen scientists. More than 65,000 have registered with our smart-matching tool Fox Trial Finder (foxtrialfinder.org), which in 2016 expanded to include atypical parkinsonisms multiple system atrophy, Lewy body dementia and others. More than 1,000 have enrolled in the MJFF-sponsored Parkinson’s Progression Markers Initiative (PPMI), our landmark study launched in 2010 to jump-start the search for Parkinson’s biomarkers — disease indicators that are critical missing links in the search for next-generation PD treatments. And the study has expanded beyond the original cohort to look at genetics to track the disease process at the earliest stages of illness.

And because Parkinson’s public policy concerns have evolved with the landscape of Parkinson’s therapeutic development, in 2016, the Foundation announced its integration of the former Parkinson’s Action Network and launch of a robust policy program. Our work in three priority areas — federal research funding, drug regulation and approval, and health care delivery and reimbursement — is bringing the passion and commitment of the PD community to bear on articulating and advancing public policy that stands to affect millions of patients and families.

Drug development is a high-risk business, and sometimes a discouraging one. At The Michael J. Fox Foundation, we believe we are building the framework to tilt the odds in favor of success — identifying and accelerating the research with potential to transform every life touched by Parkinson’s. We can’t do it without you. Thank you for sharing our vision.

With gratitude,

Todd Sherer, PhD
Chief Executive Officer

Debri Brooks
Co-Founder and Executive Vice Chairman

“The Michael J. Fox Foundation, almost singlehandedly, has catapulted… research.”

—BioWorld Today, October 2016

4 The Michael J. Fox Foundation

2016 Annual Report 7
When a promising target demonstrates sustained potential to benefit people with Parkinson’s, we move quickly to coordinate an entire field of activity in support of its continued forward movement. We tackle roadblocks head-on, providing researchers with resources to generate data and build the case for high-impact ideas, and sophisticated tools that can help science move through testing and toward regulatory approval faster. This includes characterizing molecular biology, developing strategies to objectively measure pathology and treatment effects, assembling patient cohorts, and creating technology infrastructure to gather and analyze “big data” for use by researchers in MJFF-led and independent studies.

And, it’s clear that our Foundation’s “de-risking” method — a critical framework for progress — is working. Today, several symptomatic therapies for motor and non-motor symptoms are in Phase III clinical testing, with one or more expected to file for FDA approval within the calendar year; compare that to the PD landscape as recently as 2011, when not a single Parkinson’s therapy was being tested in late-stage clinical trials. And there are no fewer than nine disease-modifying therapies advancing through clinical testing that could slow, stop or even reverse progression of PD — something no current treatment is proven to do.

This progress is set against the backdrop of a new era of patient power, with a seismic opportunity for patients to partner with scientists to influence research design and outcomes. Whether volunteering for traditional or virtual clinical trials, advocating for public policy or — like those honored in this report — providing significant financial support for our work, the Parkinson’s community is more committed than ever before to getting involved. That’s why we’ve restructured our staff to add a Community Engagement team, our newest framework dedicated to helping patients and their loved ones navigate the broad range of multi-faceted opportunities to play a personal role in our mission.

Any truly patient-centric program starts from the proposition that patients are the true experts on living with disease. Today, thousands of patients and their loved ones have enrolled in Fox Insight (foxinsight.org), our online clinical study, helping researchers gain a holistic understanding of PD and revolutionizing Parkinson’s research by contributing PROs (patient-reported outcomes) on disease course, symptom progression and treatment outcomes, among other vital data. These participants are part of a growing community of citizen scientists. More than 65,000 have registered with our smart-matching tool Fox Trial Finder (foxtrialfinder.org), which in 2016 expanded to include atypical parkinsonisms multiple system atrophy, Lewy body dementia and others. More than 1,000 have enrolled in the MJFF-sponsored Parkinson’s Progression Markers Initiative (PPMI), our landmark study launched in 2010 to jump-start the search for Parkinson’s biomarkers — disease indicators that are critical missing links in the search for next-generation PD treatments. And the study has expanded beyond the original cohort to look at genetics to track the disease process at the earliest stages of illness. And because Parkinson’s public policy concerns have evolved with the landscape of Parkinson’s therapeutic development, in 2016, the Foundation announced its integration of the former Parkinson’s Action Network and launch of a robust policy program. Our work in three priority areas — federal research funding, drug regulation and approval, and health care delivery and reimbursement — is bringing the passion and commitment of the PD community to bear on articulating and advancing public policy that stands to affect millions of patients and families.

Drug development is a high-risk business, and sometimes a discouraging one. At The Michael J. Fox Foundation, we believe we are building the framework to tilt the odds in favor of success — identifying and accelerating the research with potential to transform every life touched by Parkinson’s. We can’t do it without you. Thank you for sharing our vision.

With gratitude,

Todd Sherer, PhD
Chief Executive Officer

Deborah W. Brooks
Co-Founder and Executive Vice Chairman

“The Michael J. Fox Foundation, almost singlehandedly, has catapulted... research.”

—BioWorld Today, October 2016
2016 in Photos

From top (left to right)
1. MJFF Director of Advancement Sarah Chatham, Chairman of the Board Jeff Keefer and Nadia Wagner at a research roundtable;
2. Dave Matthews and Michael J. Fox on-stage at A Funny Thing Happened on the Way to Cure Parkinson’s;
3. Board member David Einhorn with his son at Playing to Win;
4. Board member Lee Fixel and Lauren Fixel at Funny Thing;
5. Jerrod Carmichael performs at Funny Thing;
6. Vice President of Medical Communications Rachel Dolhun, MD, Senior Vice President of Research Programs Brian Fiske, PhD, and Director of Research Partnerships Katie Kopil, PhD, discuss scientific advances at a research roundtable;
7. Parkinson’s 360, a multimedia resource for patients and families, features the experiences of four people living with PD.

From top (left to right)
8. Kimberly Williams-Paisley published Where the Light Gets In, a memoir about her late mother Linda Williams, the Foundation’s first major gifts fundraiser who was diagnosed with primary progressive aphasia — a rare form of dementia;
9. Board members Tracy Pollan and Michael J. Fox with the Pollan family at Funny Thing;
10. Matt Gerson, Howard Smith, Board member Ed Kalikow and Arthur Waldbaum at Breaking PARkinson’s;
11. Public Policy Council member Jim McNasby, JD, speaks at Breaking PARkinson’s;
12. Attendees at the Parkinson’s Disease Therapeutics Conference in New York City;
13. George Stroumboulopoulos, Michael J. Fox and Board member George Stephanopoulos pose for a selfie at Funny Thing;
14. On December 13, President Obama signed the 21st Century Cares Act into law, which will have a significant impact on Parkinson’s research.
**2016 in Photos**

*From top (left to right)*

1. MJFF Director of Advancement Sarah Chatham, Chairman of the Board Jeff Keefer and Nadia Wagner at a research roundtable;
2. Dave Matthews and Michael J. Fox on-stage at *A Funny Thing Happened on the Way to Cure Parkinson’s*;
3. Board member David Einhorn with his son at *Playing to Win*;
4. Board member Lee Fixel and Lauren Fixel at *Funny Thing*;
5. Jerrod Carmichael performs at *Funny Thing*;
6. Vice President of Medical Communications Rachel Dolhun, MD, Senior Vice President of Research Programs Brian Fiske, PhD, and Director of Research Partnerships Katie Kopil, PhD, discuss scientific advances at a research roundtable;
7. Parkinson’s 360, a multimedia resource for patients and families, features the experiences of four people living with PD.

*From top (left to right)*

8. Kimberly Williams-Paisley published *Where the Light Gets In*, a memoir about her late mother Linda Williams, the Foundation’s first major gifts fundraiser who was diagnosed with primary progressive aphasia — a rare form of dementia;
9. Board members Tracy Pollan and Michael J. Fox with the Pollan family at *Funny Thing*;
10. Matt Gerson, Howard Smith, Board member Ed Kalikow and Arthur Waldbaum at *Breaking Parkinson’s*;
11. Public Policy Council member Jim McNasby, JD, speaks at *Breaking Parkinson’s*;
12. Attendees at the Parkinson’s Disease Therapeutics Conference in New York City;
13. George Stroumboulopoulos, Michael J. Fox and Board member George Stephanopoulos pose for a selfie at *Funny Thing*;
14. On December 13, President Obama signed the 21st Century Cares Act into law, which will have a significant impact on Parkinson’s research.
The Michael J. Fox Foundation is grateful to the thousands of individual, foundation and corporate donors whose generosity makes our work possible. This report lists those who made significant contributions in 2016 toward our shared mission of speeding a cure for Parkinson’s disease.

85,000 donors

$90M in research programs funded in 2016

$25M and Up
Sergey Brin

$10M–$24,999,999
Andy Grove / The Grove Foundation*

$2.5M–$9,999,999
The Farmer Family Foundation
Nike, Inc.
The Edmond J. Safra Foundation*

$1M–$2,499,999
Anonymous
Connie and Steven Ballmer
Lauren and Lee Fixel
Golub Capital*
The Estate of Errol Jacobs
Jane Comer and Charles Lantz
Leslie and Colin Masson
Christine and Sonny Whelen

$500K–$999,999
Anonymous* (2)
The Creighton Family
The Albert and Judy Glickman Family
Great Investors’ Best Ideas Foundation / Michele and Shad Rowe
RaceTrac Petroleum, Inc.
Signature Bank
Karen Pritzker and Michael Vlock*

$200K–$499,999
Anonymous
Lauren and Mark Booth*
The Estate of Lawrence L. Curtice
The Dickson Foundation*
Cheryl and David Einhorn
The Sam J. Frankino Foundation
Estate of Elfriede Grevendick
William and Margaret Fern Holmes Family Foundation
Julie and Doug Ostrower
Parkinson’s Unity Walk
The Pumpkin Foundation / Joe and Carol Reich
Shane Smith
Anne-Cecilie Engell Speyer and Rob Speyer
Bonnie and Thomas Strauss / The Bachmann-Strauss Dystonia and Parkinson’s Foundation

*Includes payment toward a multi-year gift
The Michael J. Fox Foundation is grateful to the thousands of individual, foundation and corporate donors whose generosity makes our work possible. This report lists those who made significant contributions in 2016 toward our shared mission of speeding a cure for Parkinson’s disease.

85,000 donors

$90M in research programs funded in 2016

$25M and Up

- Sergey Brin

$10M–$24,999,999

- Andy Grove/‘The Grove Foundation’

$2.5M–$9,999,999

- The Farmer Family Foundation
- Nike, Inc.
- The Edmond J. Safra Foundation*

$1M–$2,499,999

- Anonymous
- Connie and Steven Ballmer
- Lauren and Lee Fixel
- Golub Capital*
- The Estate of Errol Jacobs
- Jane Comer and Charles Lantz
- Leslie and Colin Masson
- Christine and Sonny Whelen

$500K–$999,999

- Anonymous* (2)
- The Creighton Family
- The Albert and Judy Glickman Family
- Great Investors’ Best Ideas Foundation / Michele and Shad Rowe
- RaceTrac Petroleum, Inc.
- Signature Bank
- Karen Pritzker and Michael Vlock*

$200K–$499,999

- Anonymous
- Lauren and Mark Booth*
- Estate of Lawrence L. Curtice
- The Dickson Foundation*
- Cheryl and David Einhorn
- The Sam J. Frankino Foundation
- Estate of Elfriede Grevendick
- William and Margaret Fern Holmes Family Foundation
- Julie and Doug Ostrower
- Parkinson’s Unity Walk
- The Pumpkin Foundation / Joe and Carol Reich
- Shane Smith
- Anne-Cecilie Engell Speyer and Rob Speyer
- Bonnie and Thomas Strauss / The Bachmann-Strauss Dystonia and Parkinson’s Foundation

*Includes payment toward a multi-year gift
### The Legacy Circle recognizes: Foundations and individuals who support our mission to find the cure and go out of business, planned gifts provide a major, long-term funding source that we can both plan around and leverage immediately to accelerate our research and treatments now and in the future.

If you have made estate plans that include The Michael J. Fox Foundation, contact Shirley Nagar at 212-509-0995 ext. 240 or plannedgiving@michaeljfox.org.

Learn more at michaeljfox.org/plannedgiving.
“Cures” — that is, treatments that could slow, stop, reverse or even prevent Parkinson’s progression, something no current treatment has been proven to do — remain patients’ most urgent unmet medical need. Researchers refer to this kind of treatment as “disease-modifying,” and three-quarters of The Michael J. Fox Foundation (MJFF) funding is devoted to its pursuit.

As in many diseases since the completion of the Human Genome Project in 2003, Parkinson’s research has been transformed by genetic discoveries. But these findings are meaningful to patients only when methodically translated into practical treatments. MJFF is working to ensure that translation moves as quickly and efficiently as possible.

— **Alpha-synuclein** continues to earn its status as arguably the highest priority target in Parkinson’s disease (PD) research with five patient clinical trials moving through or completing Phase I safety trials. In 2016, an experimental “vaccine” approach, developed by MJFF-awardee AFFiRiS (an Austrian biotech) reached a new milestone by showing the treatment can successfully harness antibodies against this protein that forms abnormal, toxic clumps in the brains and bodies of people with Parkinson’s.

— Researchers are currently working on therapies to address GCase dysfunction in people with GBA (glucosidase, beta, acid gene) mutations. In late 2016, an MJFF-funded team reported that GBA mutations put Parkinson's patients at higher risk of cognitive decline, particularly in the presence of certain “severe” types of GBA mutation. These findings and other current initiatives may inform how we develop therapies. In January 2017, the first trial of a drug developed by Sanofi Genzyme, began in people with GBA mutation. Notable for its potential to treat PD, the study also represents a major step forward for personalized medicine in Parkinson’s disease.

— Industry leaders continue to take notice of MJFF’s efforts to keep LRRK2 a priority target. MJFF has applied its comprehensive roadmap strategy to LRRK2 through a consortium-based approach to investigate biology, fund therapeutic development, create research tools and recruit individuals with LRRK2 mutations to participate in clinical studies. Dozens of academic laboratories and several pharmaceutical companies partner with MJFF on active LRRK2 programs, and clinical testing is expected by 2018. In 2016, a new biotech company Denali launched with LRRK2-based treatments for Parkinson’s core to its strategic business plan. In addition to the tremendous promise of genetics, MJFF is pursuing multiple therapeutic strategies that work on non-genetic targets, primarily through repurposing treatments already approved for use in other diseases.

— MJFF has helped drive investigations and trials on several drugs including isradipine (a drug used to treat high-blood pressure that may prevent the death of dopamine-producing cells); inosine (a dietary supplement that the body converts into the antioxidant urate); exenatide (a Type 2 diabetes drug that could possibly improve physical and cognitive functions); and nilotinib (a leukemia drug that could possibly reduce Parkinson’s-related toxicity). As evidence and efficacy for the drugs to treat symptoms of PD safety are known, the opportunity and timeline to accelerate for PD patient use is shortened because it is already available in the market.
“Cures” — that is, treatments that could slow, stop, reverse or even prevent Parkinson’s progression, something no current treatment has been proven to do — remain patients’ most urgent unmet medical need. Researchers refer to this kind of treatment as “disease-modifying,” and three-quarters of The Michael J. Fox Foundation (MJFF) funding is devoted to its pursuit.

As in many diseases since the completion of the Human Genome Project in 2003, Parkinson’s research has been transformed by genetic discoveries. But these findings are meaningful to patients only when methodically translated into practical treatments. MJFF is working to ensure that translation moves as quickly and efficiently as possible.

— Alpha-synuclein continues to earn its status as arguably the highest priority target in Parkinson’s disease (PD) research with five patient clinical trials moving through or completing Phase I safety trials. In 2016, an experimental “vaccine” approach, developed by MJFF-awardee AFFiRiS (an Austrian biotech) reached a new milestone by showing the treatment can successfully harness antibodies against this protein that forms abnormal, toxic clumps in the brains and bodies of people with Parkinson’s.

— Researchers are currently working on therapies to address GCase dysfunction in people with GBA (glucosidase, beta, acid gene) mutations. In late 2016, an MJFF-funded team reported that GBA mutations put Parkinson’s patients at higher risk of cognitive decline, particularly in the presence of certain “severe” types of GBA mutation. These findings and other current initiatives may inform how we develop therapies. In January 2017, the first trial of a drug developed by Sanofi Genzyme, began in people with GBA mutation. Notable for its potential to treat PD, the study also represents a major step forward for personalized medicine in Parkinson’s disease.

— Industry leaders continue to take notice of MJFF’s efforts to keep LRRK2 a priority target. MJFF has applied its comprehensive roadmap strategy to LRRK2 through a consortium-based approach to investigate biology, fund therapeutic development, create research tools and recruit individuals with LRRK2 mutations to participate in clinical studies. Dozens of academic laboratories and several pharmaceutical companies partner with MJFF on active LRRK2 programs, and clinical testing is expected by 2018. In 2016, a new biotech company Denali launched with LRRK2-based treatments for Parkinson’s core to its strategic business plan.

In addition to the tremendous promise of genetics, MJFF is pursuing multiple therapeutic strategies that work on non-genetic targets, primarily through repurposing treatments already approved for use in other diseases.

— MJFF has helped drive investigations and trials on several drugs including isradipine (a drug used to treat high-blood pressure that may prevent the death of dopamine-producing cells); inosine (a dietary supplement that the body converts into the antioxidant urate); exenatide (a Type 2 diabetes drug that could possibly improve physical and cognitive functions); and nilotinib (a leukemia drug that could possibly reduce Parkinson’s-related toxicity). As evidence and efficacy for the drugs to treat symptoms of PD safety are known, the opportunity and timeline to accelerate for PD patient use is shortened because it is already available in the market.
Emerging Therapeutic Targets

Several novel drug targets have been getting a lot of attention lately in Parkinson’s disease research—and for good reason.

— C-Abl, a protein, has shown early promise as a potential disease-modifying therapy, and The Michael J. Fox Foundation (MJFF) funded research in this area as early as 2007. While much work remains to understand C-Abl’s role in PD progression, there is increasing activity to unlock key questions about its potential. The Foundation recently provided Georgia-based biotech Inhibibake with a grant to explore the development of advanced C-Abl inhibitors that show promise in pre-clinical models in terms of safety profile and brain penetration but others through its actions in body cells. It also seems to interact with key PD drug targets proteins that cause damage to neurons and kills brain inhibitors that show promise in pre-clinical models in terms of safety profile and brain penetration. The single protein, has shown early promise as a potential disease-modifying therapy, and The Michael J. Fox Foundation (MJFF) funded research in this area as early as 2007. While much work remains to understand C-Abl’s role in PD progression, there is increasing activity to unlock key questions about its potential. The Foundation recently provided Georgia-based biotech Inhibibake with a grant to explore the development of advanced C-Abl inhibitors that show promise in pre-clinical models.

An MJF-co-funded study with Gladstone Institute found that the single protein Nrf2 is key to fighting other faulty proteins that cause damage to neurons and kills brain cells. This also seems to interact with key PD drug targets LRRK2 and alpha-synuclein, ramping up scientific interest in its actions in body cells. Steven Finkbeiner, MD, PhD, senior author of the study, said that Nrf2 is “the most protective thing we’ve ever found.”


Inhibibake

Nrf2 is key to fighting other faulty proteins that cause damage to neurons and kills brain cells. This also seems to interact with key PD drug targets LRRK2 and alpha-synuclein, ramping up scientific interest in its actions in body cells. Steven Finkbeiner, MD, PhD, senior author of the study, said that Nrf2 is “the most protective thing we’ve ever found.”
Several novel drug targets have been getting a lot of attention lately in Parkinson’s disease research — and for good reason.

— C-Abl, a protein, has shown early promise as a potential disease-modifying therapy, and The Michael J. Fox Foundation (MJJF) funded research in this area as early as 2007. While much work remains to understand C-Abl’s role in PD progression, there is increasing activity to unlock key questions about its potential. The Foundation recently provided Georgia-based biotech Inhibikaze with a grant to explore the development of advanced C-Abl inhibitors that show promise in pre-clinical models in terms of safety profile and brain penetration under other drugs.

An MJFF co-funded study with Gladstone Institute found that the single protein NR2F is key to fighting other faulty proteins that cause damage to neurons and kills brain cells. It also seems to interact with key PD drug targets. The Nrf2 that the single protein is key to fighting other faulty proteins that cause damage to neurons and kills brain cells. It also seems to interact with key PD drug targets.
We are grateful to the following companies for matching employee gifts or organizing employee giving campaigns to collectively contribute more than $1.5 million to the Foundation in 2016.

Learn more at michaeljfox.org/employermatch.
We are grateful to the following companies for matching employee gifts or organizing employee giving campaigns to collectively contribute more than $1.5 million to the Foundation in 2016.

Learn more at michaeljfox.org/employermatch.
Since its earliest days, The Michael J. Fox Foundation has been a field leader in the pursuit of Parkinson’s biomarkers — objective measures of disease risk or progression. Through varied funding and strategic initiatives, the Foundation has sought definitive diagnostics and clinical trial endpoints to speed development of promising new treatments.

The Foundation launched the Parkinson’s Progression Markers Initiative (PPMI) in 2010 to identify and validate measures of Parkinson’s disease.

Six years later, the landmark clinical study is at 33 clinical sites around the world, has enrolled 1,500 volunteers, generated a data set accessed by researchers over 1 million times and received nearly 100 applications from scientific teams worldwide for use of the study’s well-characterized biosamples.

Biotech and pharmaceutical companies increasingly look to PPMI as a model; its protocol and evolving body of results assist neuroscience groups in designing studies, integrating state-of-the-art technologies, modeling outcomes, and gaining buy-in from senior leadership who routinely are called on to make difficult funding decisions.

The dataset is now included as a resource in large-scale projects such as the Critical Path for Parkinson’s Consortium, creating tools for optimized study design, and the planned National Institute of Health Accelerating Medicines Partnership – Parkinson’s Disease program toward biomarker discovery and novel target identification.

Research conducted using PPMI assets has contributed to greater understanding of cognitive and mood changes in Parkinson’s, helped establish a genetic risk profile that may form the basis of predicting who will get Parkinson’s and refined clinical scales to measure disease progression over time. In addition to these important results, PPMI has proved the feasibility of finding specific populations (such as newly diagnosed or with genetic forms of PD) and has been a pioneer in using tools such as social media to help speed up enrollment and cut costs in a multi-year study.
Since its earliest days, The Michael J. Fox Foundation has been a field leader in the pursuit of Parkinson’s biomarkers — objective measures of disease risk or progression. Through varied funding and strategic initiatives, the Foundation has sought definitive diagnostics and clinical trial endpoints to speed development of promising new treatments.

The Foundation launched the Parkinson’s Progression Markers Initiative (PPMI) in 2010 to identify and validate measures of Parkinson’s disease.

Six years later, the landmark clinical study is at 33 clinical sites around the world, has enrolled 1,500 volunteers, generated a dataset accessed by researchers over 1 million times and received nearly 100 applications from scientific teams worldwide for use of the study’s well-characterized biosamples.

Biotech and pharmaceutical companies increasingly look to PPMI as a model; its protocol and evolving body of results assist neuroscience groups in designing studies, integrating state-of-the-art technologies, modeling outcomes, and gaining buy-in from senior leadership who routinely are called on to make difficult funding decisions.

The dataset is now included as a resource in large-scale projects such as the Critical Path for Parkinson’s Consortium, creating tools for optimized study design, and the planned National Institute of Health Accelerating Medicines Partnership - Parkinson’s Disease program toward biomarker discovery and novel target identification.

Research conducted using PPMI assets has contributed to greater understanding of cognitive and mood changes in Parkinson’s, helped establish a genetic risk profile that may form the basis of predicting who will get Parkinson’s and refined clinical scales to measure disease progression over time. In addition to these important results, PPMI has proved the feasibility of finding specific populations (such as newly diagnosed or with genetic forms of PD) and has been a pioneer in using tools such as social media to help speed up enrollment and cut costs in a multi-year study.
The Michael J. Fox Foundation (MJFF) is committed to speeding treatments to improve today’s patients’ quality of life by more adequately addressing the symptoms of Parkinson’s disease. In 2016, several experimental drugs and treatments moved into end-stage development and are anticipated to reach market within the next one to three years.

— A new extended-release formulation of amantadine, by biotech Adamas Pharmaceuticals, is entering the home stretch of clinical testing, with a decision regarding approval from the FDA expected later this year. The formulation is taken at bedtime and slowly released into the bloodstream so that peak amounts of the drug are present when it is time to wake up. The company’s progress was accelerated by the availability of a new dyskinesia rating scale developed by MJFF in response to the lack of a validated tool in this area.

— In September 2016, MJFF-funded biotech Cynapsus was acquired by pharma firm Sunovion for over half a billion dollars. The deal was made on the strength of Cynapsus’ lead product, an under-the-tongue, fast-acting “Listerine strip” addressing “off” episodes — when symptoms return before it is time for the next dose of levodopa. The treatment has now attained Phase III clinical testing and is likely to undergo review by the FDA within several months.

— Following $1.3 million in MJFF funding to drive the early stages of clinical development, Civitas (now Acorda) developed an inhaled powder formulation of levodopa — like an asthma inhaler for Parkinson’s for off-time rescue.

— During summer 2016, Israel-based biotech NeuroDerm presented positive results from a Phase II study of an under-the-skin “pump-patch” delivering levodopa and carbidopa continuously. MJFF has invested about $2.5 million in the development of the product, which aims to lessen motor fluctuations in advancing Parkinson’s disease.
The Michael J. Fox Foundation (MJFF) is committed to speeding treatments to improve today’s patients’ quality of life by more adequately addressing the symptoms of Parkinson’s disease. In 2016, several experimental drugs and treatments moved into end-stage development and are anticipated to reach market within the next one to three years.

— A new extended-release formulation of amantadine, by biotech Adamas Pharmaceuticals, is entering the home stretch of clinical testing, with a decision regarding approval from the FDA expected later this year. The formulation is taken at bedtime and slowly released into the bloodstream so that peak amounts of the drug are present when it is time to wake up. The company’s progress was accelerated by the availability of a new dyskinesia rating scale developed by MJFF in response to the lack of a validated tool in this area.

— In September 2016, MJFF-funded biotech Cynapsus was acquired by pharma firm Sunovion for over half a billion dollars. The deal was made on the strength of Cynapsus’ lead product, an under-the-tongue, fast-acting “Listerine strip” addressing “off” episodes — when symptoms return before it is time for the next dose of levodopa. The treatment has now attained Phase III clinical testing and is likely to undergo review by the FDA within several months.

— Following $1.3 million in MJFF funding to drive the early stages of clinical development, Civitas (now Acorda) developed an inhaled powder formulation of levodopa — like an asthma inhaler for Parkinson’s for off-time rescue.

— During summer 2016, Israel-based biotech NeuroDerm presented positive results from a Phase II study of an under-the-skin “pump-patch” delivering levodopa and carbidopa continuously. MJFF has invested about $2.5 million in the development of the product, which aims to lessen motor fluctuations in advancing Parkinson’s disease.
In November 2016, The Michael J. Fox Foundation named the winners of the first Parkinson’s Progression Markers Initiative (PPMI) Data Challenge. The Foundation asked data scientists to provide a model of either Parkinson’s disease subtypes or baseline predictors of progression using PPMI data. These tools could accelerate testing of new Parkinson’s treatments by helping researchers design trials and choose study volunteers.

The winners were Duygu Tosun-Turgut, PhD, for her report on the best factors for predicting slow versus fast progression of Parkinson’s utilizing MRI scans of brain structure and functionality and Unified Parkinson’s Disease Rating Scale III to create a baseline; and Fei Wang, PhD, for his outline of characterization subgroups based on clinical symptoms that may help to select new therapies. Each individual received a $25,000 award furnished by the Foundation and supported in part by GE Healthcare.

**The Challenge Accepted**
Tributees

Rita Bain
Pietro Badia
Dr. Steve Auer
James Atkinson
Eileen Artaserse
Raymond Arose
Irving Aronow
George Arnone
Rosalia Armesto
Wayne Arden
Oliver Andrews
Holly Andersen, MD
Patricia Michaels Altman
Mary Ann Alloyway
Patty and Tom Allen
Ethan C. Allen
Muhammad Ali
Steven Alexander
Allan Aks
Larry Akman
Lisette Ackerberg

Celebrate a loved one at michaeljfox.org/tribute.

JoAnne and David Bescherer
Marianna Bertucci
Lucretia Berta
Vincent Berry
George Berrell
Don and Karen Berns
Paul Berghoff
Sara Berger
Ron Berger
Leonard Berger
Robert (Bob) Bell
Shirley Beckfield
Ken Beck
Edward Baumgartner

The Michael J. Fox Foundation pays tribute to
members, friends and caregivers who gave in their
honor or memory in 2016.

Myron Bromberg
Robert Brody
Edward Brink
Bill Brennan
Barbara Calvert
Mike Callas
Cairns
Elba Arencibia and Jayne

Celebrate a loved one at michaeljfox.org/tribute.

Margot Hames
Sally Hamilton
Joan Hamlin
Jerry Hammenschmidt
Bill Harke
Rick Hanneken
Gregory Harm
Sylvania Herman
Katharine R. Harmon
Claude Harris
Dr. Gordon F. Harris
Dr. Irving Galepenn
Wendell Fulton
Scott Friedman
Eugene Friedman
Bill Geist
Marilyn Gehlbach
Daniel Gaver
Grace Gates
Brian J. Ganton, Sr.
Norm Rupoli and Rich Gallogly
Dr. Irving Galepenn
Norm Rupoli and Rich Gallogly
Brian J. gunman.
Stanton
Gracie Gaks
David Golub
Sheldon Goldstein
David Gold
Michael Fava
Louise Esiason
David Ernst
Louise Esiasen
Carmen Emmanuelle
Eiego Gurevich
Eugenia Gurevich
Florence Gursky
Loretta Gut
Amy Goldschmid
Karen Habek
Richard Haber
Mary Hanmer
Robert Hale
May Halladay
Leo J. Haman

Grace Holmes
James Holmes
Lorry Holtzclaw
William Holtzclaw
Richard E. Hoover
Hammer Hopper
Sue Horger
Bruce Horn
Steven Howey
Harold Howe
Steve Huefner
Paul Hudy
Charles, Catherine and Frank Huisking
Jackie Hunt
William Huittman
Shawn Huria
Debby Hurburt
William Hyde
Judith Pearl Ingram
Lottie Isentger
David Ivarson
Bonnie E. Jackson
Eliose Jackson
Edward Jacobs
Matthew Jacobson
Irene Jednak
Dave Jennings
Peter Jensen
James Jessen
Patricia Johnson
Stephen Johnston
George Jones
Tom Jones
Harold John Jordan
Peter Jordan
William Jordan
William Judsott
Max Keifer
Ed Kalkow
Thomas Kane
Heray Kaplan
Sean Kaplan

John Katsanos
Loba Katz
Rossind Kay
Peter Kearns
William Keller
Alice Kelley
Declan Kelly
Nancy Kelly
William A. Kelly, III
Billy Kennedy
Robert Kennedy
Lawrence Kepln
John L. Kfroes
Bill Kirbs
Kay Kueler
The Michael J. Fox Foundation pays tribute to the following individuals as well as their family members, friends and caregivers who gave in their honor or memory in 2016.

Celebrate a loved one at michaeljfox.org/tribute.
Tributes (cont.)

Vickye Knott
Norman Kleingruber
Anita Strader Knott
Seda Kiyah
Shirley Kolowrth
The Koltons
Barbara Kraly
Keith Krautz
Bernard Kritzler
Joseph Kronner
Ruth L. Krupa
Kasbo Robert
Herbert Kuriansky
William Kuhn
Boris Kurkan
Robert Lapine
Dr. John Lake
Mary Lou Lane
Steven Lane
Daniel Lancer
Marjorie Lansford
Robert Lanson
Earl Laughlin
John Lavalle
Dr. George Raiber Lee, Jr.
Emerson Lehner
Rosie Laibner
Peter Leinroth
Carol Lantke
Harry Langer
Kostas Leonartitis
Maria Leander
Arthur Leavens
Michael Lasniak
Gus Levinson
Murray Levitt
Aram Levy
Edwin Levy
Maxine Levy
Steven Levin
Wendy Litelewski
Dr. Salvatore Liguori
Reba Lilley
Aimee P. (Nancy) Lindsay
Andrew Lipschultz
Anita Lipstein
Rose Lit
Bill and Trudy Loebl
Fred Lomkin
Ruth Candler Lovett
Jon Lovrak
Ruth Lucas
Frank Lupton
Barbara Lascher
John Lydon
Shane and Catherine Maas
John Masak
Maria Adelaide Silva Macedo
Kathryn Magnani
Nora Magnani
Shahira Mahmodi
George Malek
Emmett Malloy
Peter Markov
Richard Mann
Michael J. Manning
Irene Markel
Donald Markby
Ellie Markos
Janet Marrano
Ricardo Marti
Beth Martin
Jack Martin
Richard Massey
Nelly Matomus
Jerry May
Michael Maye
Jerry Meyerson
Mitsuo McCandlish
Patsy McCleary
Ronald McCormack
Kathy McCune
Warren McFall
Jack McQuillan
Ron McIntosh
Helen M. McKenna
Patrick J. McLaughlin
Colleen McMahon-Passero
Harry McMurty
James McNabvy
Lewis and Julia Meaden
Frank R. Mecham
Carlos Medrano
Melvina Meidinger
Richard Maines
Donald Mallert
John Mendel
Richard Menikheim
Jean Menit
Bill Merritt
Joyce Metcalfe
Robert Metten
Edward Meyers
John Mikai
Jeff Mikol
Kristine and Ken Miller
Lee Miller
Audrey Mills
Don Mills
Hong Min
Norine Curran Minato
T. Mintz
Suddy Miraldo
Hanshi Mirchandani
Arif Muhammad
Herman Mohler
Gene Moll
Ann Molony
Steve Monies
Sara Montanez
Armand Montiero
Kim and Jeff Montgomery
Steve Moore
Anas Morillo
Catherine Morrison and Family
Gene Moshe
Colby and Alberto Murgia
Bob, Chris, Daisy, Michael, Andrew, Megan and Erin Murdoch
Jerome Nafieh
Robert Nahigian
Ramsay Nair
Clint Namas
Charity Hath
Maurice Nazareth
Ben Nelson
Ron Nelson
John Newlin
Donald Nichols
Stephen Nicholson
Savannah Nichols
Joseph Jacob Neidlebaksi
Gene Novell
Carol Nuss
Scott Nyahk
Richard O'Bisky
Andy O'Brien
Eileen O'Connor
Mary J. O'Connell
Bernard Okin
Michael O'Neil
Richard O'Bosky
Sarah O'Donnell
Josephine O'Sullivan
Owen Ohlson
Maurice Onwy
Herbert Onute
Harold Osborn
Theodore and Irene Osciak
James Ostroumc
Robert (Rob) Paddock
Dale Paige
Donald Paige
Francis Pallas
Dorothy Paradies
Thomas Park
Richard Parker
Robert G. Parker
Dwayne Pamplin
John Panah
Michael Passquare
Francis Passarelli
Alma and Gary Pastega
Vincent Patel
Sue Pendleton
Dwight Pettuti, Sr.
Lee Pettit
Kelly Pettrella
Kevin Peyton
Don Phillips
John Phillipson
C. Ray Pilant
Joe Pollock
Al Pittrelli
James (Jerry) Pitts
Myra Pitts
Ronald Pizzetti
Charles F. Plummer
Albert B. Polen
Corky and Steve Pollan
Dorothy Pomazan
Armond Poulin
Leland Powell
Charles Prater
Alan Preven
George Prezco
Ruth Prezco
Ana Prodi
Jiong Pring
Gregg Puckett
Robert Rundack
Pamela Rutledgebaum
Maria Quiitero
Michael Wayne Raspberry
Edan G. Rakatch, Jr.
Peter R. Raica
Richard Reagen
Kevin Reardon
Eileen Redman
Bob Reeves
David Read
Joseph Reich
Mary Reigh
Marta Reinkoff, MD
Ellen Rees
Sharon Reuvel
Lynn Rhodes
William Ribner
Donna Richars
Harry Richardson
Stanley Richmond
William Rideout
Nancy Ritow
Joseph Rivetti
Mark Robb
Dale L. Roberston
Robert Robertson, Sr.
Stanley Robin
Carter Rogers
Liane Rosenbigan
Frederick Rosenfeld
Edward Rosenmar
Antoinette Resto
Ann Ruth
Frieda and Herman Rotter
Robert Rouse
Frederick E. Rouse
Steven Rowe
John Ruark
Thomas Peter Ruben
Judith Ruben
Martha and Max Rubinstein
Cal Rudolph
Josef Ruepp
Virginia Santucci
Jesus Sarabia
Michael Scaranco
Robert Schafer
Donald Schiele
Curts Schenker
Bill Scheve
Art Schmiding
Malcolm Schmide
Paul Schneider
Jerry H. Schmeller
Miner Schrader
Ely Schranner
Richard Schucker
Henry Schultz
Joseph Schenkewicz
Carolyn Scott
Jerry Seams
George Segers
Robert Segal
Mary Lee Sielert
Holly Seiler
Sharon Seim
Robert Servais
Carole Servidio
Isabella Shamamian
John Sharpe
Sidney and Harold Slipher
Donald Shoemaker
David Short
Seyd Siddique
Zee Sideras
Michael Simon
Riker and Carol Siggbee
Richard Silverman
Vera Sklar
Deborah Smith
George Smith
John Smith
Les Smith
John Sobota
Frank Sokolosky
Lou Sondheim
Frank Somrionto
Bemard Spitzer
Robert Spitzer
John Redgwick and Meyer Stanberry
Betty Steal
Charles Edward Steinberg
Rozanne Stafford
Bita Stenger
Marion Stockkette
Vincent Stockhausen
Wayne Stone
Bomina Strauss
Howard Strauss
Mary Straz
Joseph J. Strizic
Nancy Strobel
Walt Stroud Jr.
Barbara Stopf
Emily Su
Roxa Sugar
Patricia Sulka
Arthur Sullivan
Martha Sullivan
Paula (Sands) Swartz
Richard Sweeney
Charles Tanner
Harold Taub
Helen Tay
Mel Teichman
Roderick Templeton
Paul Thorman
Frank Thole
Joe Thomas
Robert Thompson
Paul Thurston
Francis Timmers
Edith Timms
Susan J. Todd
Bennett Tom
Joy Tomimson
Michael Tooley
Avery Topoff
George Toppin
Barbara and William Townsend
cyne Trestle
Rogar Tuskerman
Leonard F. Turnbull
Frank Uribi
Frank P. Vincentino, MD
Richard VandeVorde
Alice Vanthof
Betty Varellman
James (Jim) Vaughan
Lenny Vaughan
Joseph Verden
Leonard V. Verrastro
BK Ybara
Bill and Donna Volk
Carl Volkoff
Robert Vrabiel
Bob Wade
Robert Wagner
Richard Walsh
Shula Waldman Schreib
Robert Waldman
Ward Walquist
Donald Walter
Helen Waltz
Glenn Wang
Donald Ward
Kirk Ward
David W. Warrick
Sandi Wasch
Charles Watson
John A. (Del) Watson
Barbara Weekees
Stephen D. Weinress
Morris Weisberg
David Weisman
Sarah R. Wetherbee
David L. Wetzel
George (Sonny) Whelan
Kate Whetman
Steven R. Wicoski
Martin, Sara and Samantha Willer
Harri (Honey) Wiebe
Romuald Wierzbka
Tim Wilde
Carolyn Williams
David Russell Williams
Linda Williams
Speed Williams
Katharine Williamson
Sue Wojnowski
Sylv Wolk
Ed Vermain
Ronald Wood
George Wodrich
James (Pat) Woods, Jr.
Cynthia Hayes-Worthy
John Wright
Carol Wurts
Way Wysz
Jay Yates
Kenneth Yingst
Murray Ysoppa
Charles Young
Donald Z. Zgel
Khaled Zaass
Avrom Zartisky
Conrad Zaret
Wayne Zdenek
Jakob Ziegler
Donald Zimmermann
Laverne R. Zimmerman
William Zimmerman
Ray Zoppel
Arele Zweiben
Tributes (cont.)

Vickie Knott
Norman Kleing
Anita Strader Knott
Seda Koyr
Shirley Kolln
The Koltons
Barbara Kraly
Keith Kravitz
Bernard Kriz
Joseph Kronner
 Ruth L. Krupa
Krasota Robl
Hobert Kubinsky
William Kuhn
Boris Kurbanov
Robert Lapine
Dr. John Lake
Mary Lou Lame
Steven Lane
Daniel Lachner
Lamarie Lankford
Robert Larson
Earl Laughlin
John Lavelle
Dr. George Rolle Lee, II
Emerson Lehner
Roz Liebner
Peter Leithstreth
Carol Lambe
Harry Langer
Kostas Leonartitis
Maria Lechantaki
Arthur Leesman
Michael Lesniak
Gus Levinson
Murray Levinson
Arnold Levy
Edwin Levy
Maxine Levy
Steven Lewis
Wendy Lietzow
Dr. Salvatore Luigi
Reba Liffee
Anne P. (Nancy) Lindsey
Andrew Lipschultz
Anita Lipstein
Rose Lit
Bill and Trudy Loeb
Fred Lonner
Ruth Cander Lovett
Jon Lovrak
Ruth Lucas
Frank Lupton
Barbara Luscher
John Lydon
Stanley and Catherine Maas

John Masak
Maria Adelaide Silva Macedo
Kenneth Magnani
Nora Magnani
Shahla Mahmodi
George Malek
Emmett Malloy
Peter Marcas
Richard Mann
Michael J. Manning
Irene Markel
Donald Markby
Elitte Marks
Janet Marrano
Ricardo Marti
Brett Martin
Jack Martin
Richard Massey
Nelly Matona
Jurry May
Michael Maye
Mary Meyerson
Mitsuko McCandlish
Patsy McClean
Ronald McCormack
Kathy McCune
Warren McFall
Jack McMinis
Ron McIntosh
Helen M. McKennon
Patrick J. McLaughlin
Collum McMahon-Passero
Harry McMurtry
James McNaught
Kevin McNealy
Louis and Julia Meaden
Frank R. Mecham
Carlos Medrano
Melvina Meidinger
Richard Meinecke
Edward Meyers
John Mikkel
Jeff Milko
Kristine and Ken Miller
Lea Miller
Audrey Mills
Don Mills
Hang Min
Norosen Curran Minato
T. Mintz
Saddy Mirabito
Hareesh Mirothandani

Arlv Muhammad
Herman Mohler
Gene Moll
Ann Molyneaux
Steve Mona
Sara Montanez
Armando Montoya
Kim and Jeff Montgomery
Steve Moore
Aran Morlita
Catherine Morrison and Family
Gene Moss
Colby and Albert Murguia
Chris, Dan, McKenzie, Andrew,
Nan and Erin Murdoch
Jerome Mukhi
Robert Nahagian
Ramsay Narr
Clint Names
Charityt Naq
Maurice Nazareth
Ben Nelson
Ron Nelson
John Netlines
Donald Nichols
Stephen Nicholson
Samantha Nicol
Joseph Joseph Neibalski
Gene Nies
Carol Nuss
Scott Nykhet
Richard O’bisky
Andy O’Brien
Eileen O’Connor
Mary J. O’hardy
Bemard Oki
Michael O’Neil
Harold Osborne
Theodore and Irene Olsick
James Ostrogorsk
Robert (Bob) Paddock
Dale Paige
Donald Paige
Francisco Palla
Dorothy Paradis
Thomas Park
Merrell Parker
Robert G. Parker
Dwayne Pamell
John Paron
Michael Pasquale
Francis Passarelli
Alma and Gary Pastega
Waxman Petal
Sue Pendleton
Dwright Pertaut, Sr.
Lee Peterli
Kelly Petrella

Kevin Peyton
Don Phillips
John Phillipson
C. Ray Pindal
John Pinnock
Al Pittarelli
James (Jerry) Pitts
Myriam Pitts
Ronald Plaisance
Charles F. Plumridge
Albert B. Polan
Corky and Steve Pollan
Dorothy Pomaranc
Armond Poulin
Leland Powell
Charles Prall
Alan Pray
George Prusssott
Ruth Pruscott
Ara Pruidjan
Jason Pring
Gregg Puckett
Robert Pundack
Pamela Quattlebaum
Maria Quiterio
Michael Wayne Raspberry
Edgan G. Rashak, Jr.
Peter B. Skolnik
Richard Reagen
Kevin Reardon
Eileen Redman
Bob Reeser
David Reid
Joseph Reich
Mary Reichel
Maria Reiskoff, MD
Ellen Rees
Karen Revell
Lynn Rhoades
William Ribner
Don Rising
Harry Richardson
Stanley Richardson
William Rideout
Nancy Ritzow
Joseph Rivetti
Mark Robb
Dale L. Roberson
Robert Robertson, Sr.
Stanley Robin
Carter Rogers
Liane Rosenberg
Frederick Rosenfeld
Edward Rosmarin
Antonette Rozito
Ann Roth
Frieda and Herman Rotter
Robert Rowe

Frederick E. Rose
Steven Rowe
John Ruerk
Thomas Peter Rubbo
Judith Rubinstein
Martha and Max Rubenstein
Cal Rudolph
Josef Ruemp
Virginia Santucci
Jesus Saraia
Michael Scarno
Robert Schaeffer
Donald Scheller
Curtis Schenker
Bill Schewe
Art Schmiding
Malcolm Schmidt
Paula Schneider
Harry J. Schneller
Miner Schrader
Ely Schrauner
Richard Schuckner
Henry Schulz
Joseph Schwinncker
Carolyn Scott
Jerry Stams
George Seegers
Robert Segal
Mary Lee Siebert
Holly Siler
Stuart Smith
William S.)
Carole Sirovich
Isabella Shamayian
John Sharpe
Sidney and Harold Shibler
Donald Shoemaker
David Short
Seyd Siddique
Zoe Sidera
Michael Siemon
Rike Spier and Carol Sigbee
Richard Silberman
Vera Slkier
Deborah Smol
George Smith
John Smith
Les Smith
John Sobota
Frank Sokolosky
Les Konopkin
Frank Somentino
Bemard Spitzer
Robert Spitzer
John Rodgson and Meyer
Stanberry
Betty Steel
Charles Edward Steinberg

Roscoe Stafford
Bita Stenger
Marion Stockette
Vincent Stockhausen
Wayne Stone
Bomie Strauss
Howard Strauss
Mary Straz
Joseph J. Strizic
Nancy Strobil
Walt Stroud Jr.
Barbara Strop
Fred Lonner
Bill Wyse
Helen Walthier
Glenn Wang
Donald Ward
Kirk Ward
David W. Warrick
Sander Wasch
Charles Watson
John A. (Dee) Watson
Barbara Waskes
Stephen D. Weiss
Monts Wiesenberg
David Weisman
Sarah R. Wetherbee
David L. Weitzel
George (Sunny) Whelan
Kate Whitman
Steven R. Wicinski
Martin, Sara and Samantha
Wilder
Harco (Honey) Wielke
Rommous Wibrotha
Tom Wilde
Carolyn Williams
David Russell Williams
Linda Willams

Joseph Verdon
Leonard J. Verastaco
BH Vora
Bill and Danna Volk
Carl Volkoff
Robert Vrabal
Bob Wade
Robert Wagner
Richard Waldhauser
Shula Waldman Schneber
Robert Waldman
Ward Walquist
Donald Walter
Helen Walthier
Glenn Wang
Donald Ward
Kirk Ward
David W. Warrick
Charles Watson
John A. (Dee) Watson
Barbara Waskes
Stephen D. Weiss
Monts Wiesenberg
David Weisman
Sarah R. Wetherbee
David L. Weitzel
George (Sunny) Whelan
Kate Whitman
Steven R. Wicinski
Martin, Sara and Samantha
Wilder
Harco (Honey) Wielke
Rommous Wibrotha
Tom Wilde
Carolyn Williams
David Russell Williams
Linda Willams

Speed Williams
Katherine Williamson
Sue Wojnowski
Syl Wolk
Ed Wolman
Ronald Wood
George Woodrich
Cynthia Hayes Worthy
John Wright
Carol Wurts
Walt Wyse
Jay Yates
Katherine Yingst
Murray Ypsios
Charles Young
Donald Zile
Khaled Ziaouk
Avron Zaitsky
Gordon Zilkin
Wayne Zdenek
Jabok Ziger
Donald Zimmerman
Lavonne R. Zimmerman
William Zimmerman
Ray Zoppel
Arlene Zweben

The Michael J. Fox Foundation
In Memoriam

In June 2016, The Michael J. Fox Foundation (MJFF) and the Parkinson's community mourned the passing of Muhammad Ali while celebrating his iconic presence and indomitable spirit.

Following two decades of unparalleled triumph in the boxing ring, Ali retired from the sport in 1981, shortly before his Parkinson’s disease diagnosis at age 42. With his wife, Lonnie, by his side, he shifted focus to advocacy and humanitarianism.

“Curing Parkinson’s disease once seemed impossible. But momentum is at last on our side. We believe without fail that cures are within reach if we dare to do more, not less. Muhammad Ali showed us what it means to have the heart of a champion. Now is our chance to honor him by finishing the fight he could not.”

—Michael J. Fox and Todd Sherer, PhD, CNN.com

“Impossible is not a declaration. It’s a dare.”

—Muhammad Ali
In Memoriam

In June 2016, The Michael J. Fox Foundation (MJFF) and the Parkinson’s community mourned the passing of Muhammad Ali while celebrating his iconic presence and indomitable spirit.

Following two decades of unparalleled triumph in the boxing ring, Ali retired from the sport in 1981, shortly before his Parkinson’s disease diagnosis at age 42. With his wife, Lonnie, by his side, he shifted focus to advocacy and humanitarianism.

“Curing Parkinson’s disease once seemed impossible. But momentum is at last on our side. We believe without fail that cures are within reach if we dare to do more, not less. Muhammad Ali showed us what it means to have the heart of a champion. Now is our chance to honor him by finishing the fight he could not.”

—Michael J. Fox and Todd Sherer, PhD, CNN.com

“Impossible is not a declaration. It’s a dare.”

—Muhammad Ali
In November 2016, The Michael J. Fox Foundation (MJFF) awarded three researchers prizes for their groundbreaking work in advancing therapeutic development for the benefit of those living with Parkinson’s and dystonia.

— Susan Bressman, MD, and Laurie Ozelius, PhD, accepted the second annual Bachmann-Strauss Prize for Excellence in Dystonia Research. Together, their research identified three primary or isolated dystonia genes, and they have built a repository of thousands of genes associated with dystonia. Their work also has yielded innovative imaging studies in families with these genetic associations. Created through a research alliance between MJFF and The Bachmann-Strauss Dystonia and Parkinson Foundation (BSDPF), the $100,000 prize will be shared by Drs. Bressman and Ozelius to further their individual dystonia studies.

— Ira Shoulson, MD, received the Robert A. Pritzker Prize for Leadership in Parkinson’s Research. Dr. Shoulson co-founded the Parkinson Study Group in 1985 and the Huntington Study Group in 1994, two international academic consortia devoted to research and development of treatments. He also had made key contributions to regulatory science and medicine and was formerly a Joseph P. Kennedy Jr. Foundation health policy fellow in the U.S. Senate. The $100,000 Robert A. Pritzker Prize for Leadership in Parkinson’s Research is named in honor of the late industrialist, entrepreneur and philanthropist. Renowned artist and Parkinson’s patient Tom Shannon designed the award. Dr. Shoulson will direct his prize toward advancing research on Parkinson’s patient-reported outcomes and patient preferences.
In November 2016, The Michael J. Fox Foundation (MJFF) awarded three researchers prizes for their groundbreaking work in advancing therapeutic development for the benefit of those living with Parkinson’s and dystonia.

— Susan Bressman, MD, and Laurie Ozelius, PhD, accepted the second annual Bachmann-Strauss Prize for Excellence in Dystonia Research. Together, their research identified three primary or isolated dystonia genes, and they have built a repository of thousands of genes associated with dystonia. Their work also has yielded innovative imaging studies in families with these genetic associations. Created through a research alliance between MJFF and The Bachmann-Strauss Dystonia and Parkinson Foundation (BSDPF), the $100,000 prize will be shared by Drs. Bressman and Ozelius to further their individual dystonia studies.

— Ira Shoulson, MD, received the Robert A. Pritzker Prize for Leadership in Parkinson’s Research. Dr. Shoulson co-founded the Parkinson Study Group in 1985 and the Huntington Study Group in 1994, two international academic consortia devoted to research and development of treatments. He also had made key contributions to regulatory science and medicine and was formerly a Joseph P. Kennedy Jr. Foundation health policy fellow in the U.S. Senate. The $100,000 Robert A. Pritzker Prize for Leadership in Parkinson’s Research is named in honor of the late industrialist, entrepreneur and philanthropist. Renowned artist and Parkinson’s patient Tom Shannon designed the award. Dr. Shoulson will direct his prize toward advancing research on Parkinson’s patient-reported outcomes and patient preferences.
In October 2016, Nike once again brought a piece of pop-culture history to life. The 2016 Nike Mag shoe, complete with revolutionary self-lacing technology, was unveiled to the world through an online draw and international live auctions that in total raised $6.95 million in just over a month to support the Foundation’s mission.

The limited-edition release of 89 pairs of self-lacing Nike Mag shoes just like the ones Michael J. Fox wore in Back to the Future Part II electrified film fans, sneakerheads and the PD community worldwide through the eight-day draw, auctions in Hong Kong and London and a bidding war for the final pair at the Foundation’s New York City gala in November. Speaking to Foundation Board member George Stephanopoulos on “Good Morning America,” Michael J. Fox summed up the excitement with a simple statement: “The shoes are amazing.”

Through two events generating worldwide interest in 2011 and 2016, respectively, Nike has raised more than $16 million for the Foundation’s vital work and spotlighted the urgent need for new and better treatments for Parkinson’s.

Nike’s Tiffany Beers and Tinker Hatfield at A Funny Thing Happened on the Way to Cure Parkinson’s, where the final pair of self-lacing Mags was auctioned for a record-breaking $200,000.
Generosity

In October 2016, Nike once again brought a piece of pop-culture history to life. The 2016 Nike Mag shoe, complete with revolutionary self-lacing technology, was unveiled to the world through an online draw and international live auctions that in total raised $6.95 million in just over a month to support the Foundation’s mission.

The limited-edition release of 89 pairs of self-lacing Nike Mag shoes just like the ones Michael J. Fox wore in *Back to the Future Part II* electrified film fans, sneakerheads and the PD community worldwide through the eight-day draw, auctions in Hong Kong and London and a bidding war for the final pair at the Foundation’s New York City gala in November. Speaking to Foundation Board member George Stephanopoulos on “Good Morning America,” Michael J. Fox summed up the excitement with a simple statement: “The shoes are amazing.”

Through two events generating worldwide interest in 2011 and 2016, respectively, Nike has raised more than $16 million for the Foundation’s vital work and spotlighted the urgent need for new and better treatments for Parkinson’s.

Nike’s Tiffany Beers and Tinker Hatfield at *A Funny Thing Happened on the Way to Cure Parkinson's*, where the final pair of self-lacing Mags was auctioned for a record-breaking $200,000.

The Michael J. Fox Foundation

42

2016 Annual Report
Recurring Gifts

Recurring donations provide a dependable base of support for our vital programs to speed research progress. We are grateful to these individuals who started or continued significant recurring gifts to the Foundation in 2016.

Become a monthly donor at michaeljfox.org/monthlygiving.
Recurring donations provide a dependable base of support for our vital programs to speed research progress. We are grateful to these individuals who started or continued significant recurring gifts to the Foundation in 2016.

Become a monthly donor at michaeljfox.org/monthlygiving.
Team Fox

In 2016, more than 4,200 Team Fox members around the country and all over the world brought together their local communities in shared pursuit of a cure for Parkinson’s. Together, these local champions have raised more than $10 million. Thanks to an anonymous donor, 100 percent of Team Fox proceeds went directly to the Foundation’s programs.

4,200 grassroots Team Fox fundraisers worldwide

$10M raised for Parkinson’s research in 2016

Get involved at teamfox.org

$1M and Up

Team VICE
TCS NYC Marathon

$500,000–$999,999

Mark Booth
TCS NYC Marathon
Wendy and Rick Tigner
Tour de Fox: Wine Country;
UCSF Celebrity Golf Classic
The Woods Family
New England Parkinson’s Ride

$100,000–$499,999

Susan Bilotta
Tips for Parkinson’s;
Disney Marathon Weekend;
NYC Fox Trot
Kickin’ Parkinson’s Committee
A Kickin’ Party: Crescent City Classic 10K
Delaware Pancakes Committee
Delaware Pancakes for Parkinson’s
Terry and Oliver Holler
Back to the Future Fundraisers
Karen and Marc Jaffe
Shaking with Laughter;
Tour de Fox: Great Lakes
Nicole Jarvis
Parkinson’s Research Foundation Winter Gala
Kyle Davis and Lamar Johnson
Gensler’s Big Ed Bowl
Harry McMurtry
500 Miles for Parkinson’s Research
Daniel Morris and Team PAPA D Civilian Military Combine
Donna and Mike Rajkovic
Detriot Gala for Parkinson’s Research
The Silverman Family and the Jake’s Ride Committee
Jake’s Ride
Team ESB
Pancakes for Parkinson’s
Ashley and Justin Vedder
Foxy Gala; Vedder Golf Event
Sonny Whelen
Racing for a Cure
In 2016, more than 4,200 Team Fox members around the country and all over the world brought together their local communities in shared pursuit of a cure for Parkinson’s. Together, these local champions have raised more than $10 million. Thanks to an anonymous donor, 100 percent of Team Fox proceeds went directly to the Foundation’s programs.

4,200 grassroots Team Fox fundraisers worldwide

$10M raised for Parkinson’s research in 2016

Get involved at teamfox.org

Team VICE
TCS NYC Marathon

Mark Booth
TCS NYC Marathon
Wendy and Rick Tigner
Tour de Fox: Wine Country;
UCSF Celebrity Golf Classic
The Woods Family
New England Parkinson’s Ride

$1M and Up

$500,000–$999,999

Susan Bilotta
Tips for Parkinson’s,
Disney Marathon Weekend;
NYC Fox Trot
Kickin’ Parkinson’s Committee
A Kickin’ Party: Crescent City Classic 10K
Delaware Pancakes Committee
Delaware Pancakes for Parkinson’s
Terry and Oliver Holler
Back to the Future Fundraisers
Karen and Marc Jaffe
Shaking with Laughter;
Tour de Fox: Great Lakes
Nicole Jarvis
Parkinson’s Research Foundation Winter Gala
Kyle Davis and Lamar Johnson
Gensler’s Big Ed Bowl
Harry McMurtry
500 Miles for Parkinson’s Research
Daniel Morris and Team PAPA D
Civilian Military Combine
Donna and Mike Rajkovic
Detroit Gala for Parkinson’s Research
The Silverman Family and the Jake’s Ride Committee
Jake’s Ride
Team ESB
Pancakes for Parkinson’s
Ashley and Justin Vedder
Foxy Gala; Vedder Golf Event
Sonny Whelen
Racing for a Cure

$100,000–$499,999

Team VICE
TCS NYC Marathon

Wendy and Rick Tigner
Tour de Fox: Wine Country;
UCSF Celebrity Golf Classic
The Woods Family
New England Parkinson’s Ride

The Michael J. Fox Foundation
$50K–$99,999

The Bluegrass Situation
Linda Ronstadt Tribute Concert
Tamra Cantore
Countrified Rock
Pet Erickson
Pink’s Passion for a Parkinson’s Cure
Lauren Williams, Jackie Williams and Laura Fiske
Pedaling 4 Parkinson’s
The Kober Family
Toe Off For Parkinson’s Golf Outing
Bret Parker
TCS NYC Marathon
Pettinaro Family Griddle Team
Delaware Pancakes for Parkinson’s
Team Cantore
Countrified Rock
Team CRCF Strong
New England Parkinson’s Ride
Team ParkinsonS and Daughters of Bill Giarruso
New England Parkinson’s Ride
Team PD Cure
New England Parkinson’s Ride
Team Woods
New England Parkinson’s Ride
The University of Virginia Pancakes for Parkinson’s

$25K–$49,999

Spencer Bain
TCS NYC Marathon
Jimmy Choi
NYC Fox Trot,
TCS NYC Marathon,
Tour de Fox: Pacific Northwest,
Tour de Fox: Wine Country,
Disney Marathon Weekend,
Bank of America Chicago Marathon,
Chicago Half Marathon,
Shake It Off 5K,
PD Food Fight
The Epstein Family
Pancakes for Parkinson’s
Tim Freeman
Birdies For Parkinson’s Research
Friends of Team Fox
Holiday Party
David Gardner
Jake’s Ride
Sam Gogolak
Team Fox Fundraiser
The Guberman Family
Pocono Fox Trot 5K for Parkinson’s Research
The Harmon Family
Golf for a Cure, Disney Marathon Weekend
Jack Taylor’s Alexandria Toyota-Scion
Golf and Field Day
Ryan Levine
Kids Film It Festival
Mollie Lombardi
HR Gives Back
Magic Jigsaw Puzzles
Portion of Proceeds
George Manahan and the West Virginia Fox Trot Committee
Fox Trot for Parkinson’s Research
Peter Marconi
New England Parkinson’s Ride
MarkWest Energy Partners
Bruce Gillick Memorial Fundraisers’

Zachary Mattison
TCS NYC Marathon
Toni and Gary Palumbo
Team Fox Swing for the Cure
Brett Rosenbaum
New England Parkinson’s Ride
Team Berlin
Tour de Fox Wine Country Ride
Team Chowdugs
Tour de Fox Wine Country Ride
Team Cul de Sac
Drink and Draw and Heroescon
Team Driscoll’s
Tour de Fox Wine Country Ride
Team Fox Young Professionals of NYC
Sunday Funday, Foxy Fall Masquerade Ball
Team Merrie Miles
London Marathon
Team Mojo
Jake’s Ride
Michael Westphal
Boston Marathon,
Great Run on Cranberry Island,
MDI Marathon,
TCS NYC Marathon
Anna Wistran-Wolfe
Northshore Walk for Parkinson’s
$50K–$99,999

- The Bluegrass Situation
- Linda Ronstadt Tribute Concert
- Tamra Cantore
- Countrified Rock
- Pat Erickson
- Pinky’s Passion for a Parkinson’s Cure
- Lauren Williams, Jackie Williams and Laura Fiske
- Pedaling 4 Parkinson’s
- The Kober Family
- Toe Off Fore Parkinson’s Golf Outing
- Bret Parker
- TCS NYC Marathon
- Pettinaro Family Griddle Team
- Delaware Pancakes for Parkinson’s
- Team Cantore
- Countrified Rock
- Team CRCF Strong
- New England Parkinson’s Ride
- Team ParkinsonS AND DAUGHTERS OF BILL GIARRUSO
- New England Parkinson’s Ride
- Team PD Cure
- New England Parkinson’s Ride
- Team Woods
- New England Parkinson’s Ride
- The University of Virginia
- Pancakes for Parkinson’s
- Spencer Baim
- TCS NYC Marathon
- Jimmy Choi
- NYC Fox Trot
- TCS NYC Marathon,
  Tour de Fox: Pacific Northwest,
  Tour de Fox: Wine Country,
  Disney Marathon Weekend,
  Bank of America Chicago Marathon,
  Chicago Half Marathon,
  Shake It Off 5K,
  PD Food Fight
- The Epstein Family
- Pancakes for Parkinson’s
- Tim Freeman
- Birdies Fore Parkinson’s Research
- Friends of Team Fox
- Holiday Party
- David Gardner
- Jake’s Ride
- Sam Gogolak
- Team Fox Fundraiser
- The Guberman Family
- Pocono FoxTrot 5K for Parkinson’s Research
- The Harmon Family
- Golf for a Cure, Disney Marathon Weekend
- Jack Taylor’s Alexandria Toyota-Scion
- Golf and Field Day
- Ryan Levine
- Kids Film It Festival
- Mollie Lombardi
- HR Gives Back
- Magic Jigsaw Puzzles
- Portion of Proceeds
- George Manahan and the West Virginia Fox Trot Committee
- Fox Trot for Parkinson’s Research
- Peter Marconi
- New England Parkinson’s Ride
- MarkWest Energy Partners
- Bruce Gillick Memorial Fundraisers

$25K–$49,999

- Zachary Mattison
- TCS NYC Marathon
- Toni and Gary Palumbo
- Team Fox Swing for the Cure
- Brett Rosenbaum
- New England Parkinson’s Ride
- Team Berlin
- Tour de Fox Wine Country Ride
- Team Chowdogs
- Tour de Fox Wine Country Ride
- Team Cul de Sac
- Drink and Draw and Hocuspocus
- Team Driscoll’s
- Tour de Fox Wine Country Ride
- Team Fox Young Professionals of NYC
- Sunday Funday, Foxy Fall Masquerade Ball
- Team Merrie Miles
- London Marathon
- Team Mojo
- Jake’s Ride
- Michael Westphal
- Boston Marathon,
  Great Run on Cranberry Island,
  MDI Marathon,
  TCS NYC Marathon
- Anna Wistran-Wolfe
- Northshore Walk for Parkinson’s
- Johann Laeschke running the TCS New York City Marathon for Team VICE
The Michael J. Fox Foundation (MJFF) recognizes the critical role of Parkinson’s patients and families in drug development research; as such, we have significantly expanded our efforts to engage, educate and mobilize a broad cross-section of people with PD and their loved ones.

In light of the advancing state of Parkinson’s research overall, it has become clear that bringing treatments over the finish line today requires a concerted focus on Parkinson’s public policy. In March 2016, MJFF and the Parkinson’s Action Network (PAN) announced the dissolution of PAN and MJFF’s decision to take on PAN’s mission to bolster policy and advocacy efforts serving the Parkinson’s community. The Foundation is building a policy program that addresses three priority areas: securing federal research funding for Parkinson’s, bringing effective new therapies to patients without delays or sacrificing safety, and safeguarding access to care for patients and their loved ones. MJFF also maintains strong relationships with the PD community and provides resources to help patients and their families connect with educational resources, optimized clinical care and technology-based platforms to access clinical studies.

— Launched in 2012, Fox Trial Finder connects potential PD research volunteers — patients and controls — with studies at clinical centers that need them. More than 65,000 individuals have registered to date.

— Fox Insight is a portal of virtual research opportunities where patients and controls participate remotely through prompting to report symptoms, treatments, quality of life and family medical history every 90 days. Data is anonymous and available to researchers worldwide. The platform also incorporates data from other tools such as mobile apps that work with Apple’s recently launched ResearchKit software platform, which has enrolled more than 5,000 participants since its beta launch, smartwatches and wearables.

— Our monthly research-focused webinar/podcast series features MJFF Contributing Editor Dave Iverson, a veteran journalist who himself lives with Parkinson’s. The series now routinely attracts up to three thousand registrants a month. Movement Disorders Specialist and MJFF Vice President of Medical Communications Rachel Dolhun, MD, uses digital platforms (web and social) to field the community’s most frequently asked questions, through her Ask the MD series and Facebook Live broadcasts.

—
The Michael J. Fox Foundation (MJFF) recognizes the critical role of Parkinson’s patients and families in drug development research; as such, we have significantly expanded our efforts to engage, educate and mobilize a broad cross-section of people with PD and their loved ones.

In light of the advancing state of Parkinson’s research overall, it has become clear that bringing treatments over the finish line today requires a concerted focus on Parkinson’s public policy. In March 2016, MJFF and the Parkinson’s Action Network (PAN) announced the dissolution of PAN and MJFF’s decision to take on PAN’s mission to bolster policy and advocacy efforts serving the Parkinson’s community. The Foundation is building a policy program that addresses three priority areas: securing federal research funding for Parkinson’s, bringing effective new therapies to patients without delays or sacrificing safety, and safeguarding access to care for patients and their loved ones. MJFF also maintains strong relationships with the PD community and provides resources to help patients and their families connect with educational resources, optimized clinical care and technology-based platforms to access clinical studies.

— Fox Insight is a portal of virtual research opportunities where patients and controls participate remotely through prompting to report symptoms, treatments, quality of life and family medical history every 90 days. Data is anonymous and available to researchers worldwide. The platform also incorporates data from other tools such as mobile apps that work with Apple’s recently launched ResearchKit software platform, which has enrolled more than 5,000 participants since its beta launch, smartwatches and wearables.

— Our monthly research-focused webinar/podcast series features MJFF Contributing Editor Dave Iverson, a veteran journalist who himself lives with Parkinson’s. The series now routinely attracts up to three thousand registrants a month. Movement Disorders Specialist and MJFF Vice President of Medical Communications Rachel Dolhun, MD, uses digital platforms (web and social) to field the community’s most frequently asked questions, through her Ask the MD series and Facebook Live broadcasts.

— Launched in 2012, Fox Trial Finder connects potential PD research volunteers — patients and controls — with studies at clinical centers that need them. More than 65,000 individuals have registered to date.
The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care
Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care

The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care

The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care

The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care

The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care

The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care

The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care

The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.

Optimizing Parkinson’s Care

The Michael J. Fox Foundation and AbbVie are proud that Partners in Parkinson’s has served more than 30,000 members of the Parkinson’s community from coast to coast since its launch in 2014. This strategic health initiative aims to fill in knowledge gaps and provide new educational tools and resources for the Parkinson’s community to help patients optimize their care from diagnosis through advanced disease. Combining virtual and face-to-face opportunities, including day-long symposia attracting up to 1,000 attendees, Partners in Parkinson’s empowers patients and families to “discover the benefits of team” by connecting them with information and resources that can be crucial in developing a plan of care specific to their Parkinson’s.
$5K–$9,999 (cont.)

Anna Flores
Jonathan Forman
Fox Rothschild
Fraser & Doane: Atlanta, GA
Josh Gallup
Elizabeth Garthard
Mark Cherry
Ron Giarrusso
Tom Giarrusso
Eric Giles
Jennifer Graves
Max Greenfeld
Melanie Groch
Nicholas Groch
Kevin Gaing
Hacking for a Cure for Parkinson’s Disease
Harold Halvorsen
Dan Hantman
Mark Hardymon
Jamie Heighway
Richard Henderson
Chuck Hendricks
Joshua Holt
David Holton
Alexis Hovanesian
The Howard
Marcia Howard
Independent Stave Company
Robbie Janowitz
Alyssa Johnson
Connie Jones
John Kezia
Mary Kezia
James Lee
Lead Me a Toner Team
Leo London 2017
Amy Lewing
Brian Ling
Longhorn Pancakes for Parkinson’s
Sarah Lord
Caylone Lundholm
Jonathan Mackin
George Maradan
Brian McCullers
Helen McCurdy
Korrie Miga
Sean Morin
Natalya Morgan
Morgan Morillo
Colin Mullan
Paul Murphy
 Neuroscience Institute at Main Medical Center
OC Choe Crew
Edward O’Donnell
Kenneth Oronica
Stephanie Padwick
Katherine Parker
Jasmina Parker-Leone
Parkinson YPC
Parkinson’s Pal
Families for Parkinson’s
Mike Peers
Join Rannamootu Pederson
Peloton for Parkinson’s
Megan Plaisance
Richard Poliakha
Rubbank
Michael Rentoul
Pete Repole
Ride for Diane
Mark Riggle
Rocksteadcycling.com
Rocky Mountain High
Carolin Roll
Grad Rosenhans
Jennifer Rossenweg
The Royal Tannerhausens
Diana Rutkhaford
John Ryan
Marissa Rybakcy
The Schornstein Family
James Schulte
Dan Schultz
Christopher Schublin
Anna Schublin
Jocelyn Soll
Maken, Raffles, Rules and Roads
William Shea
Kimberly Sherman
Kelly Sherr
Lewis Silberman
Jake Silverman
Rebecca Silberman
Carrie Smith
Courtney Smith
Maureen Smith
Missy Spangler Stotts
Steve Spencer
Jacob Spielberg
Steve Squires
St. Clairsville Spell for a Cure
Victoria Storoh
Jan Strombeck
Jason Surface
Stephanie Soto
Team Alleen
Team Ansen
Team B
Team Beesal
Team Brooks
Team Casamentos
Team Danny Boy Golf Tournament
Team Danny Noonan
Team Dekat Dominica
Team DK Long
Team Emily Beth
Team Family Fighting Parkinson’s
Team Family Tus
Team Ferris Mandalini
Team Gardner / Botic
Team GZ
Team Greenfield
Team Harborcuse Town Lighthouse
Team Hot Shot
Team Joy
Team Lemonade
Team Louis
Team Murray Men
Team Nordby
Team O’Donnell Aba
Team Okour
Team Olyagat
Team Pace to Pace
Team Pedalools
Team Pier’s 4 a Cure
Team Pump’s Sampler
Team Racechirch PartnerBryp
Team Rosenfroston
Team Scrambled Legs
Team Makan’ not Strudel
Team Segel
Team Silver
Team Spangler
Team Squares
Team Tyler Brown
Team Yummosi
Team Warning
Michael A. Tofano
Cindy Thedberg
Eric Tourtel
Chin Tracey
Debbie Saper-Tuck
Richard Tucker
Chermon Tawking
Unquia’s Little Men
Cali, Nita Strohbergen
Paul Vetter
Allison Wachsmont
Lady Wagner
Erika Winklerberg
Jamie Winnberg
Whales in Motion
Tim Wolf
Bruce Wolfe
Chin Woods
Esha Woods
Wyley’s Coyotes
Join Us
$2,500–$4,999
2017 Sunoco Challenge
Benjamin Achin
Danielle Achin
Gay and Mike Achin
Matilda Agarens
Henry Allen
Daniele Anderl
Stacy Ander
Robert Addo
Nancy Arnold
Anthee Marcus Cambridge
Nancy Ashbrook
Andreas Ashkin
Brockenbeaut.com
Brace Ballard
Becky Barton
Meg Booty
Robert Borto
Big & “Team Bigger!”
Jeanne Brromen
Benjamin Bramhall
Lenny Brandell
Lisa Blasowit
Michael Blamey
Andreas Bosch
Dante Bodo
Stefanie Boras
Yoko Bradfied
Jo Brass
Matt Bristl
Mark Rossbeard
Eric Brown
Sandra Brown
Peter Callaghan
Sam Caplan
Tara Carbonneau
Opposite
Bikers at the starting line for the New England Parkinson’s Ride
Left
Oasis Summer Day Camp’s annual Fox-A-Thon
Below
Ryan Levine (center right) with his family at the Kids Film It Festival

The Michael J. Fox Foundation
2016 Annual Report
Committee pose before guests
The Kickin’ Parkinson’s Right
Northwest (TWU) at Tour de Fox: Pacific
Team Trinity Western University

Abbie Johnson
Jack Jones-Ziegler
Amber Joyce
Lea and Deo Jorgensen
Brian Kasko
Bob Kaufman
Kicky’s Crusaders
Keep Jogging 4 My Brains - Round 2
Kelly’s Loggin House
John Kerstein
Michael Khalil
Brian King
Stephanie Kirwan
Gavin Knott
Phoenix Knevel
Jannine Koscier
Caitlin Kritsch
Bob Kuhn
Kevin Krek
Johann Lambino
Andrea Lambka
Bejan Le Noir
James Lim
Lizotte’s Legacy
Berta Lipton
Melvyn Lipton
David Loesser
London De Wolfe Ice Hockey Club
David Lopez
Don Lucia
Jehovah’s Men
Debra Majdal
Lisa Mandell
Paul Marking
MaryLou and Friends
Charmy McCray
Stephanie and Merrick Mcginn
Gig Maguire
Liz Means
Sandra Merzado
David Milam
Lauren Mills
Las Miles
M. Sakmate Mourou
Sabrina Molina
Susan Molchovan
Beverly Moore
Thomass Moore
Moe Cowell
James Morris
Deyala Moskow
Shauna Murphy
Cheri Myatt
Gail Nasif
Joseph Nancirian
Marina Newth
Tan Nichols
Jennifer Neuman
Jordan Norberg
Kevin Norcross
Lauren Nottara
Aza Oddy
Janelle O’Reilly
Gennie Pals
Patty for Parkinson’s
Kristen Pace
Maria Patterson
Michael Pearson
Pedaling for Parkinson’s
Rachel Pelletier
Alice Pedrazzi
Diana Pickard
Brenton Pilkko
Sally Primo
Kevin Plant
Flying Tudes on Parkinson’s
Portini
Cullen Power
Danniel Proudflock
The Philadelphia Open
Greg Purdon-Brown
Maibritt Rahn
Elizabeth Rappano
Ray & the Rogues
Linda Rapp
B C Riders
Susan Rezler
Margaret Keizel
Nurit Richman
Pats Rilling
Rock Steady Potbelly
Rocker for Richie
Rachel Rodriguez
Tom Root
Jordon Rosenberg
Ach Chicago
David Sack
Jonathan Sack
Gina Sacco
M’s Einy Friends
Cheryl Schoep
Trey Averee
Erica Sheik
Laura Sheldon
Jeff Shemitz
Wendi Segal
Sigma Xi’s Gamma Omicron Chapter
Silver Foxes
SKY Helicopters
John Sleeper
Springing Schnitz
Ryan Spiglione
Megan Stannard
Paul Stein
Hannah Stumplin
David Steury
Lori Stinger
Jason Stitler
Jennifer Stotts
Patricia Suwannasara
Tae Kapps Euphoni
Team 3 Sirens
Team Arcada
Team Bats
Team BG
Team Bryce
Team Bobby Hamilton
Team Champs
Team Clover to the Finish Line
Team Collins
Team Corrine and Get Us
Team Cool Cat Daddy
Team Darin
Team Do The Bad Thing
Team Fit Win / Park
Team Forza Mandellini
Team Fox Young Professionals of Los Angeles
Team Friday Morning Coffee
Team Gave
Team Gini
Team Happy Campers
Team Hank
Team Hot
Team Howell
Team HUCP (Healthy Urban Hobos)
Team Ingo
Team Joy’s Heart
Team MC
Team Millburn Short Hills Chinese
Team Mitten, Almonds and Pancakes
Team MoonTracks
Team Noobus
Team Page
Team Potters for Motion
Team Preparation 4’s
Team Shake n Bike
Team Shake n Rill and Roll
Team Shake n Rall and Run
Team Rousand
Team Sparks
Team Sweet Cakes
Team Take the Money to the Bank
Team TBI
Team TNT
Team University of Delaware and Christiana Care Health System
Team Whal
Team Will Run for Deprame
Team Wino
Abbe Trinkin
Toni’s Team
Bart Stangers
Thunder Alley / Paws for Parkinson’s
Bob Tokunaga
Robson Trumble
Meridith Tumwesigye
Two Moms and a Dad
Fighting Parkinson’s
University of New Brunswick (UNB) / Walk for a Cause
Undeniable
Alex Vannois
Danniel Vuillam
Barbor Vokaty
Vinos Ridge Runners
Ashley Wane
JP Waterman
Andy Whitham
Adam Weir
Wells + Associates
Andi Wensing
Lauren Werner
Winnipeg Grizzle Team
Julia Wood
Sean Woods
Taylor Woods
Laurel Wormuth
The Young Turks
Katie Zaringa

$2,500–$4,999 (cont.)
Hollie Carl
Yeon Carriero
David Chabot
Joyce Chen
Janet Clough
Colgate Field Hockey
Bryan Conner
Sarah Coskunian
Matt Crase
Creations for Parkinson’s
Dance Walk Team Fox
Dave’s Army
Bea de Vega
Hailey Drey
Donna DeGraziano
Florence Dhar
Joanna Dingler
Michael Dixon
Denise Duddles
Tom Dulias
Steve Drewes
Dwight’s Fight
Kael Earl
Emily Ebert
Dave Elliott
Sheila Egger
Stephanie Egidi
Elizabeth Eichchrom
David Ehdel
Michael Emerson
Nancy Eseyo
Monica Felio
Chris Finck
Skylar Fiesler
Alexis Flinching
Cathy Flosa
The Fox Trotters
Lauren Fregoli
Tom and Elaine Palmer
Andrea Garcia
Nancy Gapp
Lauren Gaynor
Tom Garrauino
Robert “Robbie” Galli
Shannon Geoff
Michele Golenbeek
Mathew Gosc
Elizabeth Gough
Steven Greenfield
Alain Grill
John Hakim
Megan Hadlock
Paul Hallock
Ron Hall
Ellison Hamilton
Joseph Hamilton
Rick Harrison
Michael Hartland
John Hruby
Jeremy Hinchliff
Hot Bed Running
Nikolaj Hunt
Ivy Griddle Team
Jeanne Gravor Charity
Cupcake Challenge
Jerry’s Team
Jim’s Joggers

Top
Team Trinity Western University (TWU) at Tour de Fox Pacific Northwest
Right
The Kickin’ Parkinson’s Committee pose before guests across to their Annual Kickin’ Party in Covington, LA

56 2016 Annual Report
$2,500–$4,999 (cont.)

Abbie Johnson
Jacq Jones-Ziegler
Andrea Joyce
Liz and David Jorgenson
Brian Kane
Bob Kaufman
Ricky’s Crusaders
Keep Joggin’ 4 My B*** – Round 2
Kelly’s Legion House
John Kranitz
Michael Khalid
Brian King
Stephanie Kirwan
Gavin Knott
Phoebe Knevel
Janna Krauter
Cameron Krumshe
Bob Kuh
Kevin Krek
Johan Lachappelle
Andrea Lamke
Reyan Leonard
James Lin
Lionne’s Legacy
Beauva Lipton
Jae Linton
David Looser
London Devils Ice Hockey Club
Don Lopez
Don Lucza
JubilantesME
Debra Magal
Lisa Mandell
Paul Marking
Maryann and Friends
Chancy McCray
Stephanie and Merrick McGinn
Guy McGrath
Liz Meo
Sandor Meczado
David Milam
Laura Mills
Ian Moses
Mr. Surprise (Mossoro)
Sabrina Molina
Susan Molshon
Bevannus Moore
Thomas Moore
Moe Cowell
James Morris
Deyara Mouly
Shauna Murphy
Cherie Myatt
Gail Naid
Joseph Nanarian
Marina Newirth
Tom Nolin
Jennifer Neuman
Jordan Norberg
Kevin Nossman
Lauren O’Hara
Ana Ojeda
Janelle Orzes
Genevieve Pats
Party for Parkinson’s
Kristie Pace
Maria Patterson
Michael Pearson
Pedaling for Parkinson’s
Rachel Pelletier
Aiko Peartillo
Diana Pickard
Ronny Piilo
Sally Prans
Kevin Plant
Frying Ticks on Parkinson’s
Pamela Power
Danielle Franchelle
The Providence Open
Greg Purser-Brown
Maia Rust
Elizabeth Rapaport
Ray & the Rogues
Latina Rise
2C Bike
Sue Rotter
Margaret Rozelle
Nancy Robinson
Paul Rilling
Rock Steady Potlatch
Rocket for Richie
Rachel Rodriguez
Tim Root
Jeriann Rosenfeld
Sack Chicago
David Sack
Jenifer Sack
Gina Sannino
Mr’s Every Friends
Cheryl Schopp
Traci Severs
Eric Sheldon
Laura Sheldon
Jeff Shimkus
Sherry Sigal
S igna Ni’s Gammers
Oremus Champion
Silver Foxx
SKY Helicopters
John Snell
Springing Schmidtmann
Ryan Squillante
Megan Stagg
Paul Stein
Hannah Stephenson
David Strey
Lori Stinger
Jason Stoller
Jennifer Smith
Paricia Snowman
Tae Kappo Epstein
Team 3 Sirens
Team Accola
Team Beem
Team BG
Team Bryne
Team Casey Hamilton
Team Chamo
Team Closer to the Finish Line
Team Collins
Team Come! Come! Get Us
Team Cool Cat Daddy
Team Dace
Team Do the Right Thing
Team Fit Wes / Parkus
Team Forza Mandolino
Team Fox Young Professionals of Los Angeles
Team Friday Morning Coffee
Team Gavo
Team Gini
Team Happy Campers
Team Hawk
Team Hot
Team Howell
Team HUCP (Healthy Urban Hobos)
Team Inky
Team Jo’s Heart
Team MC
Team Millburn Short Hills Chinese
Team Miller, Almonds and Pancakes
Team Moontracks
Team Noshani
Team Page
Team Perrot for Motion
Team Preparation Hy’s
Team Shake n Bikes
Team Shake n Rides and Roll
Team Shake n Rides and Run
Team Roundup
Team Sprints
Team Sweet Cakes
Team Take the Money to the Bank
Team TBI
Team TNT
Team University of Delaware and Christiana Care Health System
Team Walsh
Team Will Run for Depression
Team Wino
Abbie Tomkin
Toni’s Team
Bass Thespian
Thunder Alley / Pins for Parkinson’s
Bob Tokunaga
Reuben Trunkle
Meredith Tutteworm
Two Moms and a Dad
Fighting Parkinson’s
University of New Brunswick (UNB) / Walk for a Cause
Unshakable
Aiko Vannioso
Daniele Varriani
Baron Venter
Vince Ridge Runners
Ashley Warren
JP Warren
Andy Wetherman
Adam Weit
Wells + Associates
Amila Winninger
Lauren Winning
Wichita Griddle Team
Julia Wood
Saun Woods
Taylor Woods
Laura Wormuth
The Young Twins
Katie Zuniga

Top Team Trinity Western University (TWU) at Tour de Fox Pacific Northwest

Right The Kickin’ Parkinson’s Committee pose before guests access to the Annual Kickin’ Party in Covingston, LA
2016 Financial Highlights

At The Michael J. Fox Foundation, we take seriously our responsibility to the Parkinson’s community. We work hard to maximize every dollar to drive science with the greatest potential to benefit patients and families. Since our inception in 2000, 89 cents of every dollar we have spent has gone directly to research programs — resulting in nearly $750 million in research funded to date.

This dedication to efficiency and accountability has always been a core of our Foundation. And these values will continue to drive our progress until we deliver an end to PD, and close our doors.

The 2016 financial highlights follow. Full audited financials and our most recent IRS Form 990s are available at michaeljfox.org/annualreport
2016 Financial Highlights

At The Michael J. Fox Foundation, we take seriously our responsibility to the Parkinson’s community. We work hard to maximize every dollar to drive science with the greatest potential to benefit patients and families. Since our inception in 2000, 89 cents of every dollar we have spent has gone directly to research programs — resulting in nearly $750 million in research funded to date.

This dedication to efficiency and accountability has always been a core of our Foundation. And these values will continue to drive our progress until we deliver an end to PD, and close our doors.

The 2016 financial highlights follow. Full audited financials and our most recent IRS Form 990s are available at michaeljfox.org/annualreport
# The Michael J. Fox Foundation for Parkinson’s Research

## Consolidated Statements of Financial Position

**As of December 31**

<table>
<thead>
<tr>
<th>Assets</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$102,142,613</td>
<td>$108,518,271</td>
</tr>
<tr>
<td>Cash and cash equivalents – restricted</td>
<td>2,757,306</td>
<td>795,636</td>
</tr>
<tr>
<td>Investments</td>
<td>11,999,431</td>
<td>1,276,214</td>
</tr>
<tr>
<td>Contributions receivable, net</td>
<td>20,919,938</td>
<td>16,317,283</td>
</tr>
<tr>
<td>Charitable gift annuities</td>
<td>616,319</td>
<td>533,011</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>1,200,352</td>
<td>634,930</td>
</tr>
<tr>
<td>Inventory</td>
<td>28,256</td>
<td>38,257</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>1,041,945</td>
<td>851,153</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$140,706,360</td>
<td>$128,962,755</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$3,895,853</td>
<td>$2,679,755</td>
</tr>
<tr>
<td>Grants payable, net</td>
<td>72,959,202</td>
<td>75,551,313</td>
</tr>
<tr>
<td>Loans payable, net</td>
<td>1,150,196</td>
<td>1,150,196</td>
</tr>
<tr>
<td>Interest payable</td>
<td>469,706</td>
<td>401,917</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>1,282,264</td>
<td>560,468</td>
</tr>
<tr>
<td>Annuities payable</td>
<td>375,036</td>
<td>327,615</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>7,000</td>
<td>152,800</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>$80,139,257</td>
<td>$80,824,064</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net Assets</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$92,840,432</td>
<td>$87,863,177</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>5,438,628</td>
<td>2,306,026</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td>$98,279,060</td>
<td>$89,889,193</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Liabilities and Net Assets</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$140,706,360</td>
<td>$128,962,755</td>
</tr>
</tbody>
</table>

---

## Consolidated Statements of Activities

**As of December 31**

<table>
<thead>
<tr>
<th>Public Support and Revenue</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Total</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$46,739,810</td>
<td>$62,036,355</td>
<td>$108,796,165</td>
<td>$92,840,432</td>
</tr>
<tr>
<td>Special events</td>
<td>3,272,734</td>
<td>2,877,591</td>
<td>6,150,325</td>
<td>5,438,628</td>
</tr>
<tr>
<td>Investment income gains (losses)</td>
<td>98,147</td>
<td>—</td>
<td>98,147</td>
<td>(27,509)</td>
</tr>
<tr>
<td>Rental income</td>
<td>286,452</td>
<td>—</td>
<td>286,452</td>
<td>429,678</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>25,691</td>
<td>—</td>
<td>25,691</td>
<td>1,229,015</td>
</tr>
<tr>
<td><strong>Total public support and revenue before release of restrictions</strong></td>
<td>59,988,466</td>
<td>(59,988,466)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>99,910,244</td>
<td>0</td>
<td>99,910,244</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$90,245,875</td>
<td>—</td>
</tr>
<tr>
<td>Management and general</td>
<td>2,939,463</td>
<td>—</td>
</tr>
<tr>
<td>Fundraising</td>
<td>9,743,030</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>$102,928,368</td>
<td>—</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>4,945,480</td>
<td>—</td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td>$48,138,691</td>
<td>—</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>$53,084,172</td>
<td>—</td>
</tr>
</tbody>
</table>

---

## Growing Investments in PD Research

**Five-year Snapshot**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>$63M</td>
</tr>
<tr>
<td>2013</td>
<td>$77M</td>
</tr>
<tr>
<td>2014</td>
<td>$76M</td>
</tr>
<tr>
<td>2015</td>
<td>$87M</td>
</tr>
<tr>
<td>2016</td>
<td>$90M</td>
</tr>
</tbody>
</table>

*43% increase since 2012*

---

## Where Your Money Goes Since Inception

<table>
<thead>
<tr>
<th>Research Programs</th>
<th>Fundraising</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>89%</td>
<td>8%</td>
<td>3%</td>
</tr>
</tbody>
</table>

---

*60 The Michael J. Fox Foundation 2016 Annual Report 65*
## The Michael J. Fox Foundation for Parkinson’s Research

### Consolidated Statements of Financial Position

### As of December 31

<table>
<thead>
<tr>
<th>Asset Category</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$102,142,613</td>
<td>$108,518,271</td>
</tr>
<tr>
<td>Cash and cash equivalents – restricted</td>
<td>2,757,306</td>
<td>795,636</td>
</tr>
<tr>
<td>Investments</td>
<td>11,999,431</td>
<td>1,276,214</td>
</tr>
<tr>
<td>Contributions receivable, net</td>
<td>20,919,938</td>
<td>16,317,283</td>
</tr>
<tr>
<td>Charitable gift annuities</td>
<td>616,319</td>
<td>531,031</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>1,200,352</td>
<td>634,930</td>
</tr>
<tr>
<td>Inventory</td>
<td>28,256</td>
<td>38,257</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>1,041,945</td>
<td>851,153</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$128,962,755</strong></td>
<td><strong>$108,518,271</strong></td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

<table>
<thead>
<tr>
<th>Liability Category</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$3,895,853</td>
<td>$2,679,755</td>
</tr>
<tr>
<td>Grants payable, net</td>
<td>72,959,202</td>
<td>75,551,313</td>
</tr>
<tr>
<td>Loans payable, net</td>
<td>1,150,196</td>
<td>1,150,196</td>
</tr>
<tr>
<td>Interest payable</td>
<td>469,706</td>
<td>401,917</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>1,282,264</td>
<td>560,468</td>
</tr>
<tr>
<td>Annuities payable</td>
<td>375,036</td>
<td>327,615</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>7,000</td>
<td>152,800</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$80,139,257</strong></td>
<td><strong>$80,824,064</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net Assets</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$37,677,949</td>
<td>$30,195,017</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>22,889,154</td>
<td>17,943,674</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$60,567,103</strong></td>
<td><strong>$48,138,691</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Liabilities and Net Assets</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$140,706,360</strong></td>
<td><strong>$128,962,755</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Growing Investments in PD Research

#### Five-year Snapshot

<table>
<thead>
<tr>
<th>Year</th>
<th>Investment Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>$63M</td>
</tr>
<tr>
<td>2013</td>
<td>$77M</td>
</tr>
<tr>
<td>2014</td>
<td>$76M</td>
</tr>
<tr>
<td>2015</td>
<td>$87M</td>
</tr>
<tr>
<td>2016</td>
<td>$90M</td>
</tr>
</tbody>
</table>

**43% increase since 2012**

### Consolidated Statements of Activities

### As of December 31

<table>
<thead>
<tr>
<th>Public Support and Revenue</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$46,739,810</td>
<td>$62,036,355</td>
</tr>
<tr>
<td>Special events (net of direct benefit to donors of $1,053,788 and $1,095,431 in 2016 and 2015, respectively)</td>
<td>3,272,734</td>
<td>2,877,591</td>
</tr>
<tr>
<td>Investment income gains (losses)</td>
<td>98,147</td>
<td>—</td>
</tr>
<tr>
<td>Rental income</td>
<td>286,452</td>
<td>286,452</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>25,691</td>
<td>25,691</td>
</tr>
<tr>
<td><strong>Total Public Support and Revenue before release of restrictions</strong></td>
<td><strong>$110,411,300</strong></td>
<td><strong>$115,356,780</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$90,245,875</td>
<td>—</td>
</tr>
<tr>
<td>Management and general</td>
<td>2,939,463</td>
<td>2,939,463</td>
</tr>
<tr>
<td>Fundraising</td>
<td>9,743,030</td>
<td>9,743,030</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$102,928,368</strong></td>
<td><strong>$102,928,368</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change in net assets</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets, beginning of year</td>
<td>30,195,017</td>
<td>17,943,674</td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>37,677,949</td>
<td>22,889,154</td>
</tr>
</tbody>
</table>

**Where Your Money Goes Since Inception**

- **Research Programs**: 89%
- **Fundraising**: 8%
- **Administration**: 3%

**Total**

89% 8% 3%
Since our launch in 2000, The Michael J. Fox Foundation (MJFF) has received a steady outpouring of Canadian support. Canadian researchers have been actively involved in our scientific agenda since the earliest days and individuals from across the country invest in our research efforts or take part in Team Fox. MJFF officially registered as a Canadian charity in 2009.

### Statements of Financial Position

#### As of December 31

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current Cash</td>
<td>$ 2,772,894</td>
<td>$ 1,669,847</td>
</tr>
<tr>
<td>Cash</td>
<td>–</td>
<td>103,800</td>
</tr>
<tr>
<td>Pledge receivable</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$ 2,772,894</td>
<td>$ 1,773,647</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$ 7,956</td>
<td>$ 7,500</td>
</tr>
<tr>
<td>Grants payable</td>
<td>583,015</td>
<td>88,202</td>
</tr>
<tr>
<td>Due from The Michael J. Fox Foundation for Parkinson's Research (USA)</td>
<td>2,181,923</td>
<td>1,677,945</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>$ 1,773,647</td>
<td>$ 1,773,647</td>
</tr>
</tbody>
</table>

### Statements of Operations and Changes in Net Assets

#### Year Ended December 31

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donations</td>
<td>$ 1,355,848</td>
<td>$ 1,317,374</td>
</tr>
<tr>
<td>Other income</td>
<td>1,227</td>
<td>661</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>$ 1,357,075</td>
<td>$ 1,318,035</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research grant awards</td>
<td>$ 1,310,725</td>
<td>$ 1,300,259</td>
</tr>
<tr>
<td>Administration and other</td>
<td>46,350</td>
<td>17,776</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$ 1,357,075</td>
<td>$ 1,318,035</td>
</tr>
<tr>
<td><strong>Excess of revenue over expenses and net assets, beginning and end of year</strong></td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

2016 Annual Report
Since our launch in 2000, The Michael J. Fox Foundation (MJFF) has received a steady outpouring of Canadian support. Canadian researchers have been actively involved in our scientific agenda since the earliest days and individuals from across the country invest in our research efforts or take part in Team Fox. MJFF officially registered as a Canadian charity in 2009.

The Michael J. Fox Foundation for Parkinson’s Research
Statements of Financial Position

As of December 31

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current Cash</td>
<td>$2,772,894</td>
<td>$1,669,847</td>
</tr>
<tr>
<td>Cash</td>
<td>$103,800</td>
<td>$103,800</td>
</tr>
<tr>
<td>Pledge receivable</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$2,772,894</td>
<td>$1,773,647</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$7,500</td>
<td>$7,500</td>
</tr>
<tr>
<td>Grants payable</td>
<td>$583,015</td>
<td>$88,202</td>
</tr>
<tr>
<td>Due from The Michael J. Fox Foundation for Parkinson’s Research (USA)</td>
<td>$2,181,923</td>
<td>$1,677,945</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>$1,773,647</td>
<td>$1,773,647</td>
</tr>
</tbody>
</table>

Statements of Operations and Changes in Net Assets

Year Ended December 31

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donations</td>
<td>$1,355,848</td>
<td>$1,317,374</td>
</tr>
<tr>
<td>Other income</td>
<td>1,227</td>
<td>661</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>$1,357,075</td>
<td>$1,318,035</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research grant awards</td>
<td>$1,310,725</td>
<td>$1,300,259</td>
</tr>
<tr>
<td>Administration and other</td>
<td>46,350</td>
<td>17,776</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$1,357,075</td>
<td>$1,318,035</td>
</tr>
<tr>
<td>Excess of revenue over expenses and net assets, beginning and end of year</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
Frameworks for Progress
The Michael J. Fox Foundation 2016 Annual Report was published in July 2017.

Founder
Michael J. Fox

Chief Executive Officer
Todd Sherer, PhD

Co-Founder & Executive Vice Chairman
Deborah W. Brooks

Deputy Chief Executive Officer
Sonali Chowdhury

Senior Vice President, Communications and Content Strategies
Indy Tsichlholz

Editors
Deborah Bunyriak
Director, Communications
Cheryl Bowers
Associate Director, Development Communications

Publications Coordinator
Emily Murphy

Design
Simplissimus
www.simplissimus.net

Photo Credits
Cover illustration and throughout: A visual reification of the Foundation’s efforts to speed the cure for Parkinson’s by identifying critical needs in the biomedical research enterprise, creating blueprints to address those needs, and working from those blueprints to build tangible outcomes patients can feel in their everyday lives.

Pages 2 and 3
Mark Seliger

Pages 6 and 7
1, 4 – Bill Bytsura
2, 5 – Getty Images / Jamie McCarthy
3 – Filip Wolak
7 – Evan Duning

Pages 21, 25, 59
Sam Ogden

Pages 21, 25
Ann Billingsley

Page 33
Ann Billingsley

Page 37
Bill Bytsura

Page 41
Getty Images / Nicholas Hunt

Pages 49, 52-56
Courtesy of MJFF supporters and their friends and families

Credits

Board of Directors
Chairman
Jeff Kowher

Vice Chairman
Woody Shockey

Holly S. Andersen, MD

Glenn Bachelder

Mark Booth

Jim Brooks

Brenda Cohen

Andrew Coots

Dennis Deitch

David Einhorn

Karen Ferman

Lee Fiel

Neil Fortenberry

Michael J. Fox

Willee Gaet

David Glickman

David Golds

Mark H. Hart II

Skip Irving

Edward Kalenow

Amar Kuchinad

Edwin A. Levy

Marc S. Lipschultz

Ofer Nemirovsky

Andy O’Brien

Douglas E. Otvos

Tracy Pollan

George E. Prescott

Ryan Reynolds

Marc L. Raas

Bret Parker

Lydia Safta

Carolyn Schenker

Curtis Schenker

Richard J. Schnall

Anne-Dee Engrailt Sprayer

George Stephanopoulos

Benni Strauss

Rick Tyler

Fred G. Weiss

Sonny Whelan

Pete Zaffino

Founders’ Council
Lorne and Muhammad Ali
Stever A. Cohen
Albert B. Glickman
John Griffin
Andrew S. Grove
Kate Hook
Jeffrey Knosberg
Morton M. Kondracke
Nora McNiff
Donna Shaak, PhD

Leadership Council
Chairman
Richard Fitzgerald

Vice Chairman
Devy Prasad

Omar Aniel-Hale

Shabek Alam

Lori Berger

Felix Bhandari

Susan Blattet

Zachary Bres

De Choudry

John S. Daily

Terry Friel

Michael Kaplon

Julia Kelly

Justin Leopone

Pamela Mills

Rafi Sperman

Scott Schecter

Bill Shepherd

Ryan Squillante

Patient Council
Co-Chairs
David Luhren

Scotocan Mair, MD

Carl Bock, Jr.

Eugenia Brin

Ken Coker

Christopher Chadbourne

Caryn Christensen

Michael R. “Ric” Clifford

Quentin Dastugue

Steve Delbridge

Anne Cohn Donnelly, D.P.H.

David Gagner, PhD

Bilchrist Gist

Cynthia Gray

Lynn Hagerbrant

Karen Jaffe, MD

Nicole Jaffe, MD

Tony Mendez

Hilton Minkay, MD

Brad Parker

Eric Fischer

Bryan Roberts

Israel Roboldio

Richa Rotenberg

Margaret Shaver

Din Susan

W.N. (Bill) Wilkins

Executive Scientific Advisory Board
Bartan Bxson, MD, PhD

Ted Dawson, MD, PhD

John DuBusk, PhD

Steven Finklebee, MD, PhD

Thomas Gaspari, MD, PhD

Kabana M. Merchant, PhD

Michael Schainklik, MD, PhD

Taran Simrul, MD

Matthew Steyn, MD

Melvin Tanset, PhD

Public Policy Council
Melissa Benasch

Davide B Design, MD

Col. Karl B. Fried, PhD, BE

David Higgins, PhD

Julie W. Holken, Jr.

Mark Kasevich

Rod Lane

Jesica Lawrence-Vaca

Daniel Lewis, JD

Maxine Lindsay, JD

Jim McNabey, JD

Jeff Sturck

Anne J. Ullal, PhD

Board and Councils

Boards and Councils
When the cure for Parkinson’s is found — and it will be — it will be because of all of us, working together.

—Michael J. Fox
When the cure for Parkinson’s is found — and it will be — it will be because of all of us, working together.

—Michael J. Fox